Fatal Familial Insomnia

Mendelian MONDO:0010808 Pathograph 8 Show in embeddings browser

Fatal familial insomnia (FFI) is a very rare, invariably fatal autosomal dominant genetic prion disease caused by the PRNP c.532G>A (p.Asp178Asn, D178N) variant in cis with methionine at the codon-129 polymorphism. It is one of the three classic inherited prion phenotypes, alongside Gerstmann-Straussler-Scheinker syndrome and genetic Creutzfeldt-Jakob disease. The clinical signature is progressive, polysomnographically demonstrable disintegration of sleep - loss of spindles and K-complexes, then abolition of NREM sleep, with enacted dreams (oneiric stupor) intruding on wakefulness - together with sympathetic autonomic overactivity and motor signs (myoclonus, ataxia, dysarthria, dysphagia, pyramidal signs), advancing to an akinetic, mute, dysautonomic state and death typically within months to about three years. The neuropathological hallmark is severe, preferential degeneration of the anteroventral and mediodorsal thalamic nuclei with astrogliosis and inferior olivary involvement, and comparatively little spongiform change. FFI is notable for two things beyond its rarity: it is the disease that established that a single pathogenic PRNP mutation can specify two different diseases depending on a common polymorphism in cis (129M gives FFI, 129V gives familial CJD), and its molecular signature - a 19 kDa type-2 protease-resistant PrP fragment - behaves as a distinct transmissible prion strain.

Ask OpenScientist

Ask a research question about Fatal Familial Insomnia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
17
Phenotypes
1
Hypotheses
3
Gaps
8
Pathograph
5
Genes
4
Medical Actions
2
Subtypes
1
Trials
1
References
1
Deep Research
👪

Inheritance

1
Autosomal dominant HP:0000006
FFI is inherited in an autosomal dominant manner; each child of a heterozygous carrier has a 50% chance of inheriting the variant. Penetrance is high and age-dependent but not absolute - GeneReviews notes carriers who remain asymptomatic because of reduced penetrance. Age at onset is strikingly variable (reported onsets span roughly 19 to 68 years within the single D178N-129M molecular subtype), and disease duration is co-determined by the codon-129 genotype of the non-mutant allele.
Autosomal dominant inheritance Penetrance: INCOMPLETE Expressivity: VARIABLE
Show evidence (3 references)
PMID:20301407 SUPPORT Human Clinical
"50% chance of inheriting the variant"
GeneReviews states the autosomal dominant 50% transmission risk for genetic prion disease.
PMID:20301407 SUPPORT Human Clinical
"asymptomatic because of reduced penetrance"
GeneReviews documents reduced penetrance in some PRNP variant carriers.
PMID:37626863 SUPPORT Human Clinical
"disease with a wide variability in age of onset"
Documents the wide variability in age at onset within FFI (D178N-129M).
◆

Subtypes

2
FFI, codon-129 methionine homozygote (short course)
Patients homozygous for methionine at codon 129 (i.e. 129M on both the mutant and the wild-type allele) run a short clinical course of roughly 9 months and present with the classic insomnia/oneiric/dysautonomic picture.
Show evidence (1 reference)
PMID:9669701 SUPPORT Human Clinical
"oneiric episodes, insomnia and dysautonomia at onset, whereas heterozygotes"
Homozygotes at codon 129 present with prominent oneiric episodes, insomnia, and dysautonomia.
FFI, codon-129 methionine/valine heterozygote (prolonged course)
Patients heterozygous methionine/valine at codon 129 run a markedly prolonged course (mean about 31 months), present more often with ataxia and dysarthria, lose sphincter control earlier, may have generalized seizures, and show more extensive cortical involvement on FDG-PET and at autopsy.
Show evidence (1 reference)
PMID:9669701 SUPPORT Human Clinical
"showed ataxia and dysarthria at onset, earlier sphincter loss and epileptic"
Defines the distinct presenting features of the codon-129 heterozygous subtype.
◈

Mechanistic Hypotheses

1
Native-State Thermodynamic Destabilization of PrP-C
native_state_destabilization ⚠ DEPRECATED
⚠ Overturned model — shown for reference, not as current mechanism

DisMech records superseded hypotheses explicitly rather than deleting them, so that claims still circulating in reviews, textbooks and older diagnostic criteria can be checked against an assessment. This model is not part of the disease mechanism DisMech asserts.

Citation volume does not decide standing here. A hypothesis may retain more supporting than refuting citations simply because the supporting literature accumulated for decades before the refutation landed; where the two conflict, DisMech follows the more recent and more direct evidence. Supporting citations below are retained for the historical record.

Evidence balance 3 refute
The historical model that familial PRNP substitutions cause disease by lowering the thermodynamic (and kinetic) stability of the folded C-terminal domain of PrP-C, so that the native alpha-helical fold more readily slips into a beta-sheet-rich, conversion-competent conformer. It is intuitive and still widely repeated, but it was tested directly and does not hold: measured stabilities of the familial-mutant proteins do not correlate with disease phenotype, and PrP-C folding is too fast and too cooperative to expose a folding-intermediate route to PrP-Sc. Recorded here as a DEPRECATED hypothesis rather than silently deleted, because an earlier revision of this entry asserted it as the mechanism of the "Acquisition of a Conversion-Prone PrP-C State" node, and the intuition is likely to be reintroduced by a future curator unless the refuting evidence stays attached to the claim it refutes.
Deprecating this hypothesis does not resolve the mechanism - it only removes a wrong answer. How the D178N-129M haplotype actually confers conversion propensity, and why the same substitution with 129V yields familial CJD instead, remains open; see the strain-identity knowledge-gap discussion on this entry.
Show evidence (3 references)
PMID:9813003 REFUTE In Vitro
"some hereditary forms of prion disease cannot be rationalized using the concept of mutation-induced thermodynamic destabilization of the cellular prion protein"
The paper set out to test this exact hypothesis for the FFI (M129/D178N), GSS (P102L) and familial CJD (E200K) variants and concluded against it. D178N could not even be assayed because it aggregated; P102L was indistinguishable from wild-type and E200K only very slightly destabilized.
PMID:10079068 REFUTE In Vitro
"These data suggest that destabilization of PrPC is neither a general mechanism underlying the formation of PrPSc nor the basis of disease phenotypes in inherited human TSEs."
Independent replication across all eight disease-associated substitutions in the structured C-terminal domain: five destabilize it and three do not, and the stabilities do not track disease phenotype.
PMID:10360358 REFUTE In Vitro
"propagation of the abnormal, oligomeric prion protein PrP(Sc), which is supposed to be the causative agent of transmissible spongiform encephalopathies, is unlikely to follow a mechanism where kinetic folding intermediates of PrP(C) are a source of PrP(Sc) subunits"
Refutes the kinetic half of the hypothesis specifically. Stopped-flow folding of the structured domain has a half-life of about 170 microseconds with no detectable intermediates, so a populated folding intermediate is not available as the PrP-Sc precursor. Species/construct caveat: measured on murine mPrP(121-231) carrying an engineered F175W fluorescence reporter - not human PrP and not the D178N-129M haplotype - so the argument is a cross-species extrapolation resting on the conservation of the C-terminal globular fold between mouse and human PrP. The authors show the reporter variant has "the same overall structure and stability as wild-type mPrP(121-231)", which addresses the construct but not the species step.
?

Discussions and Knowledge Gaps

3
Why is the mediodorsal thalamic nucleus so selectively vulnerable in FFI, sustaining severe neuronal loss at only moderate PrP-Sc burden, when protease-resistant PrP is distributed far more widely across gray matter?
KNOWLEDGE GAP gap_ffi_thalamic_selectivity
Attached to
pathophysiology#Preferential Thalamic Neuronal Loss and Astrogliosis
Regional PrPres quantification shows accumulation is broader than the lesions, and that the mediodorsal nucleus is damaged at PrPres levels that leave other regions intact. Neither the 19 kDa strain conformation nor codon-129 phase explains why this particular nucleus is the primary target, so the cell-intrinsic determinant of thalamic vulnerability is unknown.
Proposed experiments
Spatially resolved comparison of vulnerable versus resistant thalamic nuclei
exp_ffi_thalamic_vulnerability_spatial_omics
Perform cell-type-resolved spatial transcriptomics and proteomics on FFI autopsy thalamus, comparing the mediodorsal and anteroventral nuclei against thalamic nuclei that remain histologically intact in the same brains. Test whether baseline PRNP expression level, proteostatic capacity (chaperone and ubiquitin-proteasome components), or metabolic reserve tracks with regional vulnerability after adjusting for local PrPres burden.
Pre-lesional single-nucleus profiling of D178N-129M knock-in thalamus
exp_ffi_prelesional_knockin_mouse_thalamus
Profile thalamic nuclei of D178N-129M knock-in mice at time points before histological lesions or EEG change appear, to separate primary cell-intrinsic vulnerability from secondary injury response. A vulnerability signature present pre-lesionally and restricted to the mediodorsal nucleus would support a cell-intrinsic determinant.
Can PrP-lowering therapy started inside the 13-21 month pre-symptomatic window prevent or delay clinical FFI, and what surrogate endpoint could demonstrate that?
KNOWLEDGE GAP gap_ffi_prevention_window
Attached to
pathophysiology#Template-Directed Conversion of PrP-C to FFI-Type PrP-Sc
Serial FDG-PET places the start of measurable thalamic neurodegeneration 13-21 months before onset, implying that intervention must be pre-symptomatic. But the preventive doxycycline study had to compare against a historical dataset precisely because no validated surrogate endpoint exists, and that gap now blocks efficient trials of the mechanistically stronger PrP-lowering agents.
Proposed experiments
Qualification of a composite pre-symptomatic FFI progression surrogate
exp_ffi_presymptomatic_surrogate_qualification
Follow a prospective cohort of D178N carriers with paired thalamic FDG-PET, quantitative spindle-density polysomnography, and plasma neurofilament light, anchored to observed clinical conversion. Test whether any single measure or composite changes monotonically across the 13-21 month pre-symptomatic window with enough effect size to power a prevention trial shorter than the 10-year historical-control design.
Biomarker-endpoint PRNP-lowering ASO trial in pre-symptomatic carriers
exp_ffi_presymptomatic_prnp_aso_biomarker_trial
Test intrathecal PRNP-lowering antisense oligonucleotide in pre-symptomatic D178N carriers using thalamic metabolic decline (with CSF PrP reduction as the target-engagement measure) as the primary endpoint rather than clinical conversion, pairing it with the genotype-concealing consent design that the doxycycline study showed to be acceptable to these families.
If sporadic fatal insomnia is clinically and histopathologically near-identical to FFI and carries the same 19 kDa type-2 PrP-Sc, why does it lack the glycoform skew characteristic of FFI, and does that difference mean a distinct prion strain?
KNOWLEDGE GAP gap_ffi_sfi_strain_identity
Attached to
pathophysiology#Template-Directed Conversion of PrP-C to FFI-Type PrP-Sc
Sporadic fatal insomnia patients are codon-129 methionine homozygotes without D178N, yet reproduce the FFI phenotype - implying the 19 kDa conformer, not the mutation, specifies the disease. The reproducible absence of unglycosylated-isoform underrepresentation is an unexplained molecular discrepancy that bears directly on whether glycosylation pattern is part of strain identity or a consequence of the mutant substrate.
Proposed experiments
Serial transmission comparison of FFI versus sporadic fatal insomnia isolates
exp_ffi_sfi_serial_transmission_strain_comparison
Inoculate humanized 129MM PrP transgenic mice with FFI and sporadic-fatal-insomnia brain isolates and compare incubation period, lesion profile, PrPres fragment size, and glycoform ratio across serial passages. Convergence of the glycoform ratio on serial passage would indicate the skew is substrate-determined rather than an intrinsic strain property.
Cell-free conversion test of glycoform-skew substrate dependence
exp_ffi_glycoform_substrate_dependence_pmca
Use protein misfolding cyclic amplification with mutant D178N-129M versus wild-type 129M PrP-C substrate, seeded with the same FFI-derived template, and measure whether the underrepresentation of the unglycosylated isoform requires the mutant substrate.
⚙

Pathophysiology

7
PRNP D178N-129M Germline Allele
A heterozygous PRNP p.Asp178Asn allele, carried in cis with methionine at codon 129, is present from conception in every cell. The cis-phase is part of the lesion: the same amino-acid substitution with valine at codon 129 produces a different disease (familial CJD), so the pathogenic unit is the haplotype, not the codon-178 change alone.
PRNP hgnc:9449 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves PRNP (hgnc:9449). hgnc:9449 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Acquisition of a Conversion-Prone PrP-C State
Show evidence (1 reference)
PMID:1439789 SUPPORT Human Clinical
"The Met129, Asn178 allele segregated with FFI in all 15 affected members of five kindreds whereas the Val129, Asn178 allele segregated with the familial CJD subtype in all 15 affected members of six kindreds."
Names the specific pathogenic haplotype that segregates with FFI.
Acquisition of a Conversion-Prone PrP-C State
The D178N substitution, in cis with 129M, renders PrP-C prone to adopting the misfolded, self-templating conformer that seeds propagation. Recombinant human PrP carrying the FFI M129/D178N haplotype is markedly aggregation-prone: unlike the GSS (P102L) and familial CJD (E200K) variants, which are recovered soluble, the D178N protein partitions into inclusion bodies. This is a gain of toxic conformation, not a loss of PrP function.
protein folding GO:0006457 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal protein folding (GO:0006457). GO:0006457 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Template-Directed Conversion of PrP-C to FFI-Type PrP-Sc
Show evidence (1 reference)
PMID:9813003 SUPPORT In Vitro
"whereas the D178N variant aggregated into inclusion bodies"
Recombinant human PrP(90-231) carrying the FFI M129/D178N haplotype partitions into inclusion bodies, where the P102L and E200K variants are recovered soluble from the same expression system - so aggregation propensity distinguishes this haplotype from the other familial variants. Tagged PARTIAL rather than SUPPORT deliberately: inclusion-body formation in E. coli is an aggregation observation and a common expression artifact, not a clean proxy for self-templating conversion propensity in vivo, and the authors draw no such inference themselves - they report it only as the reason D178N could not be assayed.
Template-Directed Conversion of PrP-C to FFI-Type PrP-Sc
The autocatalytic core of the disease: a misfolded PrP molecule recruits and refolds native PrP-C, so that the conformation itself acts as the replicating template. In FFI the resulting protease-resistant core is a 19 kDa (type 2) fragment with marked underrepresentation of the unglycosylated glycoform - a molecular signature distinct from the 21 kDa fragment of sporadic and other inherited prion diseases. Inoculation of FFI brain extract into chimeric human-mouse PrP transgenic mice reproduces the 19 kDa fragment, establishing that conformation, not sequence, carries the strain information.
protein homooligomerization GO:0051260 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased protein homooligomerization (GO:0051260). GO:0051260 is a biological process from the Gene Ontology. ↑ INCREASED protein refolding GO:0042026 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased protein refolding (GO:0042026). GO:0042026 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Regionally Selective PrP-Sc Accumulation in Gray Matter
Show evidence (3 references)
PMID:8953038 SUPPORT Human Clinical
"of PrPSc after deglycosylation has a size of 19 kilodaltons, whereas that from"
Establishes the 19 kDa FFI-specific protease-resistant PrP fragment.
PMID:8953038 SUPPORT Model Organism
"chimeric human-mouse PrP gene about 200 days after inoculation and induced"
Transmission to transgenic mice shows the conformer is a self-templating, transmissible strain.
PMID:8953038 SUPPORT Model Organism
"formation of the 19-kilodalton PrPSc fragment"
The inoculated mice generate the FFI-type 19 kDa fragment rather than the 21 kDa CJD fragment.
Regionally Selective PrP-Sc Accumulation in Gray Matter
Protease-resistant PrP accumulates in gray matter but not white matter or peripheral organs, and its distribution is broader than the histological lesions: lesions appear only where a critical amount of the abnormal protein has accumulated. The kinetics are region-specific - the mediodorsal thalamic nucleus and brainstem carry comparable amounts regardless of disease duration, whereas neocortical accumulation rises with duration, so the process spreads over time.
medial dorsal nucleus of thalamus UBERON:0002739 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in medial dorsal nucleus of thalamus (UBERON:0002739). UBERON:0002739 is an anatomical location from the Uberon multi-species anatomy ontology. anterior nuclear group of thalamus UBERON:0002788 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in anterior nuclear group of thalamus, annotated with anterior nuclear group (UBERON:0002788). UBERON:0002788 is an anatomical location from the Uberon multi-species anatomy ontology. inferior olivary complex UBERON:0002127 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in inferior olivary complex (UBERON:0002127). UBERON:0002127 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Preferential Thalamic Neuronal Loss and Astrogliosis
Show evidence (3 references)
PMID:7611720 SUPPORT Human Clinical
"was detected in gray matter but not in white matter and peripheral organs"
Establishes the gray-matter-restricted distribution of protease-resistant PrP in FFI.
PMID:7611720 SUPPORT Human Clinical
"it was more widespread in the subjects with a longer clinical"
The accumulation spreads within the brain as the disease progresses.
PMID:9222180 SUPPORT Human Clinical
"PrPres formation is the cause of neuronal dysfunction in prion diseases."
Links PrPres accumulation causally to neuronal dysfunction in prion disease.
Preferential Thalamic Neuronal Loss and Astrogliosis
The defining lesion: marked neuronal depletion and astrocytic gliosis concentrated in the mediodorsal and anteroventral thalamic nuclei, with inferior olivary hypertrophy and only limited cortical spongiosis. The mediodorsal nucleus appears intrinsically more vulnerable - it sustains severe neuronal loss at relatively moderate PrP-Sc burden - which is why FFI is a thalamic disease rather than a diffuse encephalopathy.
thalamic projection neuron CL:0000679 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves thalamic projection neuron, annotated with glutamatergic neuron (CL:0000679). CL:0000679 is a cell type from the Cell Ontology. reactive astrocyte CL:0000127 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves reactive astrocyte, annotated with astrocyte (CL:0000127). CL:0000127 is a cell type from the Cell Ontology.
astrocyte activation GO:0048143 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased astrocyte activation (GO:0048143). GO:0048143 is a biological process from the Gene Ontology. ↑ INCREASED neuron apoptotic process GO:0051402 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased neuron apoptotic process (GO:0051402). GO:0051402 is a biological process from the Gene Ontology. ↑ INCREASED
medial dorsal nucleus of thalamus UBERON:0002739 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in medial dorsal nucleus of thalamus (UBERON:0002739). UBERON:0002739 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Collapse of Thalamocortical Sleep Oscillation
Loss of Thalamolimbic Autonomic Restraint
Show evidence (3 references)
PMID:9669701 SUPPORT Human Clinical
"marked neuronal loss and gliosis in the thalamus, especially the medio-dorsal"
Establishes the thalamic neuronal loss and gliosis that define FFI neuropathology.
PMID:9669701 SUPPORT Human Clinical
"and anterior-ventral nuclei, olivary hypertrophy and some spongiosis of the"
Names the anteroventral nucleus and olivary hypertrophy, with only some cortical spongiosis.
PMID:7611720 SUPPORT Human Clinical
"In the mediodorsal thalamic nucleus, however, a severe neuronal loss"
The mediodorsal nucleus shows severe loss at moderate PrPres burden, indicating selective vulnerability.
Collapse of Thalamocortical Sleep Oscillation
Destruction of thalamic relay and reticular circuitry abolishes the thalamocortical oscillations that generate sleep spindles, K-complexes, and slow-wave sleep. The result is not ordinary insomnia but a failure to build sleep: spindles and K-complexes disappear early, NREM sleep is eventually abolished, and only brief residual REM periods without atonia persist, intruding into wakefulness as enacted dreams. FFI is the clinical experiment that implicated the thalamus as necessary for sleep generation.
circadian sleep/wake cycle GO:0042745 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased circadian sleep/wake cycle (GO:0042745). GO:0042745 is a biological process from the Gene Ontology. ↓ DECREASED regulation of circadian sleep/wake cycle GO:0042749 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal regulation of circadian sleep/wake cycle (GO:0042749). GO:0042749 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Show evidence (3 references)
PMID:7607093 SUPPORT Human Clinical
"an early reduction in sleep spindles and K complexes, and a drastic reduction in"
Documents early loss of the thalamocortical spindle/K-complex signature.
PMID:7607093 SUPPORT Human Clinical
"abolition of NREM sleep and persistence of only brief residual periods of REM"
Shows complete NREM abolition with residual REM in the short-course cases.
PMID:12849238 SUPPORT Human Clinical
"Intriguing clinicopathological correlations in FFI and SFI suggest a role for"
Frames the thalamolimbic system as the sleep-regulatory structure implicated by FFI.
Loss of Thalamolimbic Autonomic Restraint
Loss of thalamolimbic output releases sympathetic outflow, producing the sustained autonomic overactivity of FFI - tachycardia, hypertension, hyperhidrosis, and hyperthermia. Heart-rate-variability work shows the picture is not purely sympathetic excitation: parasympathetic (vagal) indices are also reduced relative to controls and to CJD, so cardiovascular dysautonomia reflects combined sympathetic activation and parasympathetic failure.
regulation of heart rate GO:0002027 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal regulation of heart rate (GO:0002027). GO:0002027 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Show evidence (3 references)
PMID:12849238 SUPPORT Human Clinical
"Both disorders have clinical features of disrupted sleep (loss of sleep spindles and slow-wave sleep and enacted dreams during rapid-eye-movement sleep), autonomic hyperactivation, and motor abnormalities (myoclonus, ataxia, dysarthria, dysphagia, and pyramidal signs)."
Autonomic hyperactivation is a core feature of the FFI phenotype.
PMID:36472576 SUPPORT Human Clinical
"Cardiovascular dysautonomia in FFI may be partly attributable to"
HRV evidence that parasympathetic dysfunction contributes, not sympathetic overactivity alone.
PMID:36472576 SUPPORT Human Clinical
"parasympathetic abnormalities, not just sympathetic activation"
States explicitly that parasympathetic abnormality is part of FFI dysautonomia.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Fatal Familial Insomnia Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

17
Cardiovascular 1
Tachycardia HP:0001649 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Tachycardia (HP:0001649). HP:0001649 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36472576 SUPPORT Human Clinical
"higher heart rate with a lower amplitude of oscillations"
Quantitative HRV evidence of persistent tachycardia with blunted oscillation in FFI.
Digestive 1
Dysphagia HP:0002015 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysphagia (HP:0002015). HP:0002015 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:12849238 SUPPORT Human Clinical
"abnormalities (myoclonus, ataxia, dysarthria, dysphagia, and pyramidal signs)"
Dysphagia is listed among the motor abnormalities of FFI.
Integument 1
Hyperhidrosis HP:0000975 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hyperhidrosis (HP:0000975). HP:0000975 is a phenotype from the Human Phenotype Ontology.
Sweating is a standard component of the documented FFI sympathetic hyperactivation, but no quotable FFI-specific abstract naming hyperhidrosis was found; per the project evidence SOP the claim is recorded here rather than attached to a snippet that does not mention sweating. The general dysautonomia phenotype above carries the evidence.
Musculoskeletal 1
Spasticity and pyramidal signs HP:0001257 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spasticity (HP:0001257). HP:0001257 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:9669701 SUPPORT Human Clinical
"manifestations (myoclonus, ataxia, dysarthria, spasticity)"
Spasticity is listed among the somatomotor manifestations of FFI.
Nervous System 11
Progressive insomnia VERY_FREQUENT HP:0100785 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Insomnia (HP:0100785), qualified as course progressive. HP:0100785 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (3 references)
PMID:1346338 SUPPORT Human Clinical
"progressive insomnia, dysautonomia, and motor signs"
Progressive insomnia is the defining clinical triad element in the original FFI description.
PMID:12849238 SUPPORT Human Clinical
"loss of sleep spindles and slow-wave sleep and enacted dreams"
Specifies the polysomnographic character of the sleep loss.
PMID:7607093 SUPPORT Human Clinical
"impairment of sleep-wake regulation is a consistent distinctive feature of FFI"
Frequency anchor for VERY_FREQUENT: "consistent distinctive feature" is a qualitative universal-class statement, mapping to the 80-100% band.
Loss of sleep spindles and K-complexes VERY_FREQUENT Sleep disturbance HP:0002360 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal sleep architecture on polysomnography, annotated with Sleep disturbance (HP:0002360). HP:0002360 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:7607093 SUPPORT Human Clinical
"All patients showed an early reduction in sleep spindles and K complexes"
Frequency anchor for VERY_FREQUENT: all 6 patients in the longitudinal polygraphic series showed early spindle and K-complex reduction. VERY_FREQUENT rather than OBLIGATE is the conservative reading at n=6.
PMID:7607093 SUPPORT Human Clinical
"total sleep time and disruption of the cyclic sleep organization"
Documents reduced total sleep time and loss of cyclic sleep organization on 24-hour polygraphy.
PMID:16399807 SUPPORT Human Clinical
"analysis disclosed an impaired thalamic sleep spindle formation"
Impaired spindle formation is detectable even pre-symptomatically.
Oneiric stupor with enacted dreams REM sleep behavior disorder HP:5200291 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is REM sleep behavior disorder (HP:5200291). HP:5200291 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:12849238 SUPPORT Human Clinical
"during rapid-eye-movement sleep), autonomic hyperactivation, and motor"
Enacted dreams during REM sleep are part of the core FFI sleep phenotype.
PMID:9669701 SUPPORT Human Clinical
"oneiric episodes, insomnia and dysautonomia at onset, whereas heterozygotes"
Oneiric episodes are prominent at onset in codon-129 methionine homozygotes.
Dysautonomia Abnormal autonomic nervous system physiology HP:0012332 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal autonomic nervous system physiology (HP:0012332), qualified as course progressive. HP:0012332 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (3 references)
PMID:1346338 SUPPORT Human Clinical
"progressive insomnia, dysautonomia, and motor signs"
Dysautonomia is one of the three defining clinical elements of FFI.
PMID:9669701 SUPPORT Human Clinical
"disturbances of the wake-sleep cycle, dysautonomia and somatomotor"
Names dysautonomia as one of the three characterizing feature groups of FFI.
PMID:36472576 SUPPORT Human Clinical
"sympathetic hyperactivity with preserved parasympathetic activity has been extensively recognized in fatal familial insomnia (FFI)"
Establishes that sympathetic hyperactivity is the extensively recognized autonomic picture in FFI. The assumption of preserved parasympathetic activity stated here is what this study then challenges (see the pathophysiology node).
Myoclonus HP:0001336 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myoclonus (HP:0001336). HP:0001336 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:12849238 SUPPORT Human Clinical
"abnormalities (myoclonus, ataxia, dysarthria, dysphagia, and pyramidal signs)"
Myoclonus is listed among the characteristic motor abnormalities of FFI.
Ataxia HP:0001251 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ataxia (HP:0001251), qualified as course progressive. HP:0001251 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (2 references)
PMID:12849238 SUPPORT Human Clinical
"abnormalities (myoclonus, ataxia, dysarthria, dysphagia, and pyramidal signs)"
Ataxia is a characteristic motor abnormality in FFI.
PMID:9669701 SUPPORT Human Clinical
"showed ataxia and dysarthria at onset, earlier sphincter loss and epileptic"
Ataxia is the typical presenting motor sign in codon-129 heterozygotes.
Dysarthria HP:0001260 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysarthria (HP:0001260). HP:0001260 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:12849238 SUPPORT Human Clinical
"abnormalities (myoclonus, ataxia, dysarthria, dysphagia, and pyramidal signs)"
Dysarthria is a characteristic motor abnormality in FFI.
Memory impairment HP:0002354 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Memory impairment (HP:0002354). HP:0002354 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:8780067 SUPPORT Human Clinical
"memory deficits, mainly of the working memory"
Documents the working-memory-predominant memory deficit in FFI.
PMID:8780067 SUPPORT Human Clinical
"impairment of temporal ordering of events"
Impaired temporal ordering accompanies the memory deficit.
Progressive confusional state HP:0001289 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Confusion (HP:0001289), qualified as course progressive. HP:0001289 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (2 references)
PMID:8780067 SUPPORT Human Clinical
"a progressive dream-like state with"
Names the progressive dream-like confusional state as the FFI cognitive endpoint.
PMID:8780067 SUPPORT Human Clinical
"that is distinct from the cortical and subcortical"
Basis for not classifying the FFI cognitive syndrome as a classical dementia.
Bilateral tonic-clonic seizure HP:0002069 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bilateral tonic-clonic seizure (HP:0002069). HP:0002069 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:9669701 SUPPORT Human Clinical
"showed ataxia and dysarthria at onset, earlier sphincter loss and epileptic"
Epileptic grand mal seizures were observed in the codon-129 heterozygous group.
Progressive neurologic deterioration HP:0002344 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Progressive neurologic deterioration (HP:0002344). HP:0002344 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301407 SUPPORT Human Clinical
"The disease course ranges from a few months in gCJD"
GeneReviews describes the short, progressive course of FFI and gCJD.
Constitutional 1
Urinary incontinence HP:0000020 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Urinary incontinence (HP:0000020). HP:0000020 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:9669701 SUPPORT Human Clinical
"showed ataxia and dysarthria at onset, earlier sphincter loss and epileptic"
Earlier sphincter loss characterizes the codon-129 heterozygous subtype.
Other 1
Impaired attention and vigilance Short attention span HP:0000736 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Short attention span (HP:0000736). HP:0000736 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:8780067 SUPPORT Human Clinical
"early impairment of attention and vigilance"
Attention and vigilance impairment is the earliest neuropsychological deficit in FFI.
🧬

Genetic Associations

5
PRNP
Gene: PRNP hgnc:9449 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PRNP (hgnc:9449). hgnc:9449 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:1346338 SUPPORT Human Clinical
"PrP codon 178 that results in the substitution of asparagine for aspartic"
Identifies the causal D178N substitution in PRNP.
PMID:1346338 SUPPORT Human Clinical
"Fatal familial insomnia is a prion disease with a mutation in codon"
Establishes FFI as a PRNP-linked prion disease.
PRNP codon 129 (M129V) cis-phase determinant
Gene: PRNP hgnc:9449 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PRNP (hgnc:9449). hgnc:9449 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: MODIFIER variant_origin: GERMLINE
Show evidence (3 references)
PMID:1439789 SUPPORT Human Clinical
"segregated with FFI in all 15 affected members of five kindreds whereas the"
The Met129-Asn178 allele segregates with FFI while Val129-Asn178 segregates with familial CJD.
PMID:1439789 SUPPORT Human Clinical
"to a single pathogenic mutation can be determined by a common polymorphism"
States the general principle that a common polymorphism specifies which disease the D178N mutation causes.
PMID:9669701 SUPPORT Human Clinical
"patients ran either a short (9.1 +/- 1.1 months) or a prolonged (30.8 +/-"
Quantifies the codon-129 effect on disease duration.
EXOC1L
Gene: EXOC1L hgnc:53433 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is EXOC1L (hgnc:53433). hgnc:53433 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: MODIFIER variant_origin: GERMLINE
Show evidence (2 references)
PMID:37626863 SUPPORT Human Clinical
"was observed in two pseudogenes (NR1H5P, GNA13P1) and three protein coding genes"
Names the candidate non-PRNP modifier loci; the evidence is exploratory, hence PARTIAL.
PMID:37626863 SUPPORT Human Clinical
"These genetic variants are absent in FFI patients"
The candidate variants segregate with later onset and are absent in early-onset patients.
SRSF11
Gene: SRSF11 hgnc:10782 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SRSF11 (hgnc:10782). hgnc:10782 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: MODIFIER variant_origin: GERMLINE
Show evidence (1 reference)
PMID:37626863 SUPPORT Human Clinical
"was observed in two pseudogenes (NR1H5P, GNA13P1) and three protein coding genes"
Names the candidate non-PRNP modifier loci; the evidence is exploratory, hence PARTIAL.
MSANTD3
Gene: MSANTD3 hgnc:23370 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is MSANTD3 (hgnc:23370). hgnc:23370 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: MODIFIER variant_origin: GERMLINE
Show evidence (2 references)
PMID:37626863 SUPPORT Human Clinical
"was observed in two pseudogenes (NR1H5P, GNA13P1) and three protein coding genes"
Names the candidate non-PRNP modifier loci; the evidence is exploratory, hence PARTIAL.
PMID:37626863 SUPPORT Human Clinical
"The biological function of these genes and PRNP is associated with programmed cell death, caspase-mediated cleavage of cytoskeletal proteins"
Links the candidate modifier gene set and PRNP to programmed cell death and caspase-mediated cytoskeletal cleavage biology.
💊

Medical Actions

4
Multidisciplinary supportive and palliative care
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
No disease-modifying therapy exists. Management is supportive: sleep-symptom management, autonomic and cardiac monitoring, nutrition and swallowing assessment, fall prevention, physical/occupational/speech therapy, psychiatric and caregiver support, advance care planning, and palliative care. Sedatives may reduce distress but do not restore sleep architecture, and polypharmacy can worsen confusion, falls, and respiratory risk.
Show evidence (2 references)
PMID:20301407 SUPPORT Human Clinical
"Supportive care by a multidisciplinary team"
GeneReviews recommends multidisciplinary supportive care as the mainstay of management.
PMID:20301407 SUPPORT Human Clinical
"genetic prion disease is available."
GeneReviews confirms no treatment of the underlying cause is available.
Close periodic surveillance
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Because progression is very rapid, GeneReviews recommends review by the multidisciplinary team approximately every 14 days to reassess symptomatic needs.
Show evidence (1 reference)
PMID:20301407 SUPPORT Human Clinical
"periodic monitoring by the multidisciplinary team is needed, typically every 14"
GeneReviews surveillance interval for genetic prion disease.
Genetic counseling and predictive testing
Action: genetic counselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is genetic counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. Ontology label: Genetic Counseling NCIT:C15240
Autosomal dominant risk counseling with a 50% transmission risk, predictive-testing protocols for at-risk adults that respect the right not to know, and reproductive options including preimplantation genetic testing. GeneReviews considers predictive testing of asymptomatic minors inappropriate for this adult-onset condition. The ethical weight of the right not to know is unusually prominent in FFI: the preventive doxycycline study was designed around participants' refusal to learn their own genotype, enrolling carriers and non-carriers together under a genotype-concealing scheme.
Show evidence (2 references)
PMID:20301407 SUPPORT Human Clinical
"Predictive testing in minors (i.e., testing of asymptomatic at-risk individuals younger than age 18 years) is considered inappropriate."
GeneReviews addresses the appropriateness of predictive testing in minors.
PMID:35737759 SUPPORT Human Clinical
"include both carriers of the FFI mutation (10 subjects), and non-carriers (15"
The trial design that accommodated participants' wish not to learn their genotype.
Doxycycline (preventive, investigational)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: doxycycline CHEBI:50845 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses doxycycline (CHEBI:50845). CHEBI:50845 is a therapeutic agent from Chemical Entities of Biological Interest.
Doxycycline was selected for pre-symptomatic prevention on the basis of preclinical anti-prion activity, good blood-brain-barrier penetration, and a known safety profile. In the preventive study, 10 D178N carriers over 42 years old received 100 mg/day and 15 non-carriers received placebo under a genotype-concealing design, with incidence compared against a historical dataset over 10 years. The published material establishes feasibility and design, not proven prevention.
Show evidence (3 references)
PMID:25996399 SUPPORT Human Clinical
"doxycycline, an antibiotic with anti-prion activity"
States the anti-prion rationale for doxycycline; preventive efficacy is unresolved, hence PARTIAL.
PMID:25996399 SUPPORT Human Clinical
"over 42 y old will be treated with doxycycline (100 mg/die)"
Documents the dose and eligible population in the preventive study.
PMID:35737759 SUPPORT Human Clinical
"repurposing of doxycycline - an antibiotic with a known safety profile and"
Describes the repurposing rationale; outcome data were not available at publication.
🔬

Biochemical Markers

2
Protease-resistant PrP (PrP-Sc) type 2, 19 kDa (INCREASED)
Show evidence (2 references)
PMID:10371520 SUPPORT Human Clinical
"the relative molecular mass of 19 kDa, corresponding to the so-called type 2,"
Defines the 19 kDa type-2 PrP-Sc that identifies FFI.
PMID:1346338 SUPPORT Human Clinical
"Protease-resistant PrP was found in both patients with fatal familial"
Original demonstration of protease-resistant PrP in FFI brain.
CSF total tau (INCREASED)
Show evidence (2 references)
PMID:34487324 SUPPORT Human Clinical
"Increased CSF tau was found in more than half of FFI and T188K gCJD cases"
Quantifies elevated CSF total tau in the majority of FFI cases.
PMID:34487324 SUPPORT Human Clinical
"Increased CSF tau was unusual in P102L GSS but was quite common in the other subtypes of gPrD, including D178N FFI"
Confirms CSF tau elevation is common specifically in D178N FFI.
🔬

Diagnosis

8
PRNP sequencing with codon-129 phasing
Diagnosis is established by identifying the heterozygous PRNP c.532G>A (D178N) pathogenic variant. Because the same substitution causes familial CJD when carried in cis with 129V, the codon-129 allele on the mutant chromosome must be determined - genotyping codon 129 without phasing is insufficient. Chromosomal microarray, karyotype, and repeat-expansion testing have no role.
molecular genetic testing NCIT:C19770 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:20301407 SUPPORT Human Clinical
"proband with suggestive findings and a heterozygous PRNP pathogenic variant"
GeneReviews diagnostic criterion for genetic prion disease including FFI.
PMID:1439789 SUPPORT Human Clinical
"segregated with FFI in all 15 affected members of five kindreds whereas the"
Justifies why codon-129 phasing is diagnostically necessary rather than optional.
Polysomnography
Polysomnography measures the defining physiological lesion directly: loss of sleep spindles and K-complexes, drastic reduction in total sleep time, loss of cyclic sleep organization, and eventual abolition of NREM sleep with residual REM without atonia. It is the most informative ancillary test in FFI.
polysomnography NCIT:C114185 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:7607093 SUPPORT Human Clinical
"an early reduction in sleep spindles and K complexes, and a drastic reduction in"
Polysomnography demonstrates the characteristic FFI sleep abnormalities.
FDG-PET showing thalamic hypometabolism
18F-FDG PET consistently shows severely reduced glucose utilization in the thalamus with mild cingulate hypometabolism - the functional hallmark of FFI. Cortical involvement is broader in patients with a longer course. Hypometabolism extends beyond the histopathological lesions and correlates with PrPres distribution.
positron emission tomography procedure NCIT:C17007 NCI Thesaurus (NCIT)
Show evidence (3 references)
PMID:9222180 SUPPORT Human Clinical
"hypometabolism of the thalamus and cingulate cortex is the"
Thalamic plus cingulate hypometabolism is described as the hallmark of FFI.
PMID:8255458 SUPPORT Human Clinical
"widespread brain hypometabolism involving the majority of cortical structures,"
Documents the more widespread cortical hypometabolism seen in clinically complex cases.
PMID:9222180 SUPPORT Human Clinical
"hypometabolism was more widespread in the MET/VAL129 group"
Relates the extent of hypometabolism to codon-129 genotype and disease duration.
Pre-symptomatic thalamic hypometabolism in mutation carriers
Serial FDG-PET and polysomnography in asymptomatic D178N carriers were normal 21 to 63 months before onset, but selective thalamic hypometabolism with impaired spindle formation appeared about 13 months before clinical presentation - placing the start of measurable neurodegeneration in a narrow 13-21 month pre-symptomatic window. This defines the therapeutic window for any preventive intervention.
positron emission tomography procedure NCIT:C17007 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:16399807 SUPPORT Human Clinical
"selective hypometabolism was detected in the thalamus while spectral-EEG"
Pre-symptomatic thalamic hypometabolism detected 13 months before onset.
PMID:16399807 SUPPORT Human Clinical
"FFI begins in the thalamus between 13 and 21 months before the clinical"
Establishes the pre-symptomatic onset window of the neurodegenerative process.
CSF RT-QuIC (low sensitivity in D178N FFI)
Real-time quaking-induced conversion is the modern seeding assay for prion disease, but it performs worst in FFI of all the common genetic prion subtypes. In the Chinese national surveillance series the D178N group had the lowest RT-QuIC positivity rate of any subtype at 15.8%, against 63.6% for P102L GSS and a 32.3% overall rate. Clinically decisive point: a negative CSF RT-QuIC does NOT exclude FFI, and PRNP sequencing remains the diagnostic test. Curation note on the comparator: the source is internally inconsistent about which GSS allele carries the 63.6% rate - its abstract says P105L, its results and discussion sections say P102L. P102L is used here because it matches the body text and the quoted snippet. Do not "correct" this against the abstract.
cerebrospinal fluid analysis NCIT:C173272 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:34487324 SUPPORT Human Clinical
"The highest RT-QuIC positivity rate (63.6%) was in the P102L group and lowest (15.8%) in the D178N group"
Quantifies the low RT-QuIC sensitivity in D178N FFI relative to other genetic prion subtypes.
CSF 14-3-3 (frequently negative in D178N FFI)
CSF 14-3-3, a classic surrogate marker of rapid neuronal injury in Creutzfeldt-Jakob disease, is frequently negative in FFI. Positivity concentrates in genetic CJD with C-terminal PRNP mutations (after amino acid 188) and is specifically not characteristic of P102L GSS or D178N FFI, so a negative result has no exclusionary value here.
cerebrospinal fluid analysis NCIT:C173272 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:34487324 SUPPORT Human Clinical
"CSF 14-3-3 showed high positivity rates, particularly in gCJD patients with a point mutation in the C-terminal (after aa 188), but not in P102L and D178N cases."
Establishes that CSF 14-3-3 is not a reliable positive marker in D178N FFI.
Brain MRI (low yield in D178N FFI)
The sporadic-CJD MRI signature - cortical ribboning on DWI, caudate/putamen hyperintensity, and pulvinar/posterior-thalamic signal - is informative across most genetic prion subtypes but specifically not in FFI. Only 25.5% of D178N cases showed any such abnormality, versus 92.3% of P102L cases and a 66.0% overall rate, and all three individual MRI abnormalities were low in D178N. A normal or nonspecific MRI is therefore the expected finding in FFI.
magnetic resonance imaging procedure NCIT:C16809 NCI Thesaurus (NCIT)
Show evidence (3 references)
PMID:34487324 SUPPORT Human Clinical
"MRI scanning is helpful for most types of gPrD with positivity rates similar to sCJD, except for D178N FFI"
States explicitly that MRI is the exception - unhelpful - in D178N FFI.
PMID:34487324 SUPPORT Human Clinical
"only 25.5% (12/47) of D178N cases showed such an abnormality"
Quantifies the low MRI positivity rate in D178N FFI.
PMID:34487324 SUPPORT Human Clinical
"all three MRI abnormalities in D178N FFI patients were clearly low"
All three sporadic-CJD MRI abnormalities are individually low-yield in FFI.
EEG (periodic sharp wave complexes essentially absent)
The periodic sharp wave complexes that support a diagnosis of sporadic Creutzfeldt-Jakob disease are effectively absent in FFI: only 1 of 48 D178N cases showed PSWCs, against 48.5% of E200K genetic CJD cases. EEG in FFI is instead useful for spectral analysis of sleep architecture (see polysomnography), not for the classic periodic pattern.
electroencephalography NCIT:C38054 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:34487324 SUPPORT Human Clinical
"Only one out of 48 cases of D178N FFI showed PSWCs on the EEG"
Quantifies the near-absence of the classic CJD periodic EEG pattern in FFI.
📈

Progression

1
Onset is typically in the sixth decade (GeneReviews gives 50-60 years for genetic prion disease broadly), though reported FFI onsets span roughly 19 to 68 years. The course is continuously progressive and death follows within months to about three years. Duration is bimodal by the codon-129 genotype of the non-mutant allele: about 9 months in methionine homozygotes versus about 31 months in methionine/valine heterozygotes. In national surveillance data, FFI and GSS patients tend to present earlier than point-mutation genetic CJD patients.
Show evidence (3 references)
PMID:20301407 SUPPORT Human Clinical
"ranges from 50 to 60 years"
GeneReviews typical age at onset for genetic prion disease including FFI.
PMID:9669701 SUPPORT Human Clinical
"patients ran either a short (9.1 +/- 1.1 months) or a prolonged (30.8 +/-"
Quantifies the bimodal disease duration by codon-129 genotype.
PMID:34487324 SUPPORT Human Clinical
"insomnia (FFI) cases usually displayed clinical symptoms earlier than genetic"
National surveillance data on relative age at onset of FFI versus genetic CJD.
🔬

Clinical Trials

1
NCT06153966 PHASE_I ACTIVE_NOT_RECRUITING
PrProfile - a Phase 1/2a first-in-human study of intrathecal ION717, an antisense oligonucleotide that lowers PrP by degrading PRNP mRNA, in patients with prion disease. PrP lowering acts upstream of conformational conversion and is therefore mechanistically applicable to FFI.
Show evidence (1 reference)
clinicaltrials:NCT06153966 SUPPORT Human Clinical
"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717."
The active PrP-lowering ASO programme relevant to genetic prion disease including FFI.
{ }

Source YAML

click to show 
name: Fatal Familial Insomnia
creation_date: "2026-07-29T12:00:00Z"
category: Mendelian
disease_term:
  preferred_term: fatal familial insomnia
  term:
    id: MONDO:0010808
    label: fatal familial insomnia
synonyms:
- FFI
- familial fatal insomnia
- genetic fatal insomnia
references:
- reference: PMID:20301407
  title: "Genetic Prion Disease"
  tags:
  - GeneReviews
description: >-
  Fatal familial insomnia (FFI) is a very rare, invariably fatal autosomal dominant
  genetic prion disease caused by the PRNP c.532G>A (p.Asp178Asn, D178N) variant in
  cis with methionine at the codon-129 polymorphism. It is one of the three classic
  inherited prion phenotypes, alongside Gerstmann-Straussler-Scheinker syndrome and
  genetic Creutzfeldt-Jakob disease. The clinical signature is progressive,
  polysomnographically demonstrable disintegration of sleep - loss of spindles and
  K-complexes, then abolition of NREM sleep, with enacted dreams (oneiric stupor)
  intruding on wakefulness - together with sympathetic autonomic overactivity and
  motor signs (myoclonus, ataxia, dysarthria, dysphagia, pyramidal signs), advancing
  to an akinetic, mute, dysautonomic state and death typically within months to about
  three years. The neuropathological hallmark is severe, preferential degeneration of
  the anteroventral and mediodorsal thalamic nuclei with astrogliosis and inferior
  olivary involvement, and comparatively little spongiform change. FFI is notable for
  two things beyond its rarity: it is the disease that established that a single
  pathogenic PRNP mutation can specify two different diseases depending on a common
  polymorphism in cis (129M gives FFI, 129V gives familial CJD), and its molecular
  signature - a 19 kDa type-2 protease-resistant PrP fragment - behaves as a distinct
  transmissible prion strain.
inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  penetrance: INCOMPLETE
  expressivity: VARIABLE
  description: >-
    FFI is inherited in an autosomal dominant manner; each child of a heterozygous
    carrier has a 50% chance of inheriting the variant. Penetrance is high and
    age-dependent but not absolute - GeneReviews notes carriers who remain asymptomatic
    because of reduced penetrance. Age at onset is strikingly variable (reported onsets
    span roughly 19 to 68 years within the single D178N-129M molecular subtype), and
    disease duration is co-determined by the codon-129 genotype of the non-mutant
    allele.
  evidence:
  - reference: PMID:20301407
    reference_title: "Genetic Prion Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "50% chance of inheriting the variant"
    explanation: GeneReviews states the autosomal dominant 50% transmission risk for genetic prion disease.
  - reference: PMID:20301407
    reference_title: "Genetic Prion Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "asymptomatic because of reduced penetrance"
    explanation: GeneReviews documents reduced penetrance in some PRNP variant carriers.
  - reference: PMID:37626863
    reference_title: "Genetic Variants Associated with the Age of Onset Identified by Whole-Exome Sequencing in Fatal Familial Insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "disease with a wide variability in age of onset"
    explanation: Documents the wide variability in age at onset within FFI (D178N-129M).

has_subtypes:
- name: 129MM
  display_name: FFI, codon-129 methionine homozygote (short course)
  description: >-
    Patients homozygous for methionine at codon 129 (i.e. 129M on both the mutant and
    the wild-type allele) run a short clinical course of roughly 9 months and present
    with the classic insomnia/oneiric/dysautonomic picture.
  evidence:
  - reference: PMID:9669701
    reference_title: "Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "oneiric episodes, insomnia and dysautonomia at onset, whereas heterozygotes"
    explanation: Homozygotes at codon 129 present with prominent oneiric episodes, insomnia, and dysautonomia.
- name: 129MV
  display_name: FFI, codon-129 methionine/valine heterozygote (prolonged course)
  description: >-
    Patients heterozygous methionine/valine at codon 129 run a markedly prolonged
    course (mean about 31 months), present more often with ataxia and dysarthria, lose
    sphincter control earlier, may have generalized seizures, and show more extensive
    cortical involvement on FDG-PET and at autopsy.
  evidence:
  - reference: PMID:9669701
    reference_title: "Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "showed ataxia and dysarthria at onset, earlier sphincter loss and epileptic"
    explanation: Defines the distinct presenting features of the codon-129 heterozygous subtype.

genetic:
- name: PRNP
  gene_term:
    preferred_term: PRNP
    term:
      id: hgnc:9449
      label: PRNP
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    Causal gene. FFI is caused by the heterozygous germline missense variant PRNP
    c.532G>A (p.Asp178Asn, historically D178N), which eliminates a Tth111 I
    restriction site. The lesion is a toxic conformational gain of function, not
    haploinsufficiency: the encoded PrP is not non-functional but conformationally
    unfaithful.
  evidence:
  - reference: PMID:1346338
    reference_title: "Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PrP codon 178 that results in the substitution of asparagine for aspartic"
    explanation: Identifies the causal D178N substitution in PRNP.
  - reference: PMID:1346338
    reference_title: "Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fatal familial insomnia is a prion disease with a mutation in codon"
    explanation: Establishes FFI as a PRNP-linked prion disease.
- name: PRNP codon 129 (M129V) cis-phase determinant
  gene_term:
    preferred_term: PRNP
    term:
      id: hgnc:9449
      label: PRNP
  relationship_type: MODIFIER
  variant_origin: GERMLINE
  notes: >-
    The common PRNP M129V polymorphism is not merely a severity modifier here but a
    disease-determining second genetic component. D178N in cis with 129M segregates
    with FFI; the same D178N in cis with 129V segregates with a familial CJD subtype.
    Separately, the codon-129 genotype of the non-mutant allele (MM vs MV) governs
    disease duration and the breadth of cortical involvement. Laboratories must
    therefore phase codon 129, not merely genotype it.
  evidence:
  - reference: PMID:1439789
    reference_title: "Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "segregated with FFI in all 15 affected members of five kindreds whereas the"
    explanation: The Met129-Asn178 allele segregates with FFI while Val129-Asn178 segregates with familial CJD.
  - reference: PMID:1439789
    reference_title: "Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "to a single pathogenic mutation can be determined by a common polymorphism"
    explanation: States the general principle that a common polymorphism specifies which disease the D178N mutation causes.
  - reference: PMID:9669701
    reference_title: "Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients ran either a short (9.1 +/- 1.1 months) or a prolonged (30.8 +/-"
    explanation: Quantifies the codon-129 effect on disease duration.
- name: EXOC1L
  gene_term:
    preferred_term: EXOC1L
    term:
      id: hgnc:53433
      label: EXOC1L
  relationship_type: MODIFIER
  variant_origin: GERMLINE
  notes: >-
    Candidate later-onset modifier locus nominated by an exploratory whole-exome
    study of 25 D178N-129M patients; the associated variants were absent from the
    early-onset (19-40 years) group. Unreplicated statistical association, not a
    clinically validated modifier allele.
  evidence:
  - reference: PMID:37626863
    reference_title: "Genetic Variants Associated with the Age of Onset Identified by Whole-Exome Sequencing in Fatal Familial Insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "was observed in two pseudogenes (NR1H5P, GNA13P1) and three protein coding genes"
    explanation: Names the candidate non-PRNP modifier loci; the evidence is exploratory, hence PARTIAL.
  - reference: PMID:37626863
    reference_title: "Genetic Variants Associated with the Age of Onset Identified by Whole-Exome Sequencing in Fatal Familial Insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These genetic variants are absent in FFI patients"
    explanation: The candidate variants segregate with later onset and are absent in early-onset patients.
- name: SRSF11
  gene_term:
    preferred_term: SRSF11
    term:
      id: hgnc:10782
      label: SRSF11
  relationship_type: MODIFIER
  variant_origin: GERMLINE
  notes: >-
    Candidate later-onset modifier locus from the same exploratory whole-exome study.
    Unreplicated; not a clinically validated modifier allele.
  evidence:
  - reference: PMID:37626863
    reference_title: "Genetic Variants Associated with the Age of Onset Identified by Whole-Exome Sequencing in Fatal Familial Insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "was observed in two pseudogenes (NR1H5P, GNA13P1) and three protein coding genes"
    explanation: Names the candidate non-PRNP modifier loci; the evidence is exploratory, hence PARTIAL.
- name: MSANTD3
  gene_term:
    preferred_term: MSANTD3
    term:
      id: hgnc:23370
      label: MSANTD3
  relationship_type: MODIFIER
  variant_origin: GERMLINE
  notes: >-
    Candidate later-onset modifier locus from the same exploratory whole-exome study.
    The study also implicated two pseudogenes, NR1H5P and GNA13P1, which are not
    modeled as separate records here because they have no protein-coding gene
    identity to bind; they are named in the cited evidence. The biological functions
    linked to this candidate set and to PRNP relate to programmed cell death and
    caspase-mediated cleavage.
  evidence:
  - reference: PMID:37626863
    reference_title: "Genetic Variants Associated with the Age of Onset Identified by Whole-Exome Sequencing in Fatal Familial Insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "was observed in two pseudogenes (NR1H5P, GNA13P1) and three protein coding genes"
    explanation: Names the candidate non-PRNP modifier loci; the evidence is exploratory, hence PARTIAL.
  - reference: PMID:37626863
    reference_title: "Genetic Variants Associated with the Age of Onset Identified by Whole-Exome Sequencing in Fatal Familial Insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The biological function of these genes and PRNP is associated with programmed cell death, caspase-mediated cleavage of cytoskeletal proteins"
    explanation: Links the candidate modifier gene set and PRNP to programmed cell death and caspase-mediated cytoskeletal cleavage biology.

mechanistic_hypotheses:
- hypothesis_group_id: native_state_destabilization
  hypothesis_label: Native-State Thermodynamic Destabilization of PrP-C
  status: DEPRECATED
  description: >-
    The historical model that familial PRNP substitutions cause disease by lowering the
    thermodynamic (and kinetic) stability of the folded C-terminal domain of PrP-C, so
    that the native alpha-helical fold more readily slips into a beta-sheet-rich,
    conversion-competent conformer. It is intuitive and still widely repeated, but it was
    tested directly and does not hold: measured stabilities of the familial-mutant
    proteins do not correlate with disease phenotype, and PrP-C folding is too fast and
    too cooperative to expose a folding-intermediate route to PrP-Sc. Recorded here as a
    DEPRECATED hypothesis rather than silently deleted, because an earlier revision of
    this entry asserted it as the mechanism of the "Acquisition of a Conversion-Prone
    PrP-C State" node, and the intuition is likely to be reintroduced by a future curator
    unless the refuting evidence stays attached to the claim it refutes.
  evidence:
  - reference: PMID:9813003
    reference_title: "Familial mutations and the thermodynamic stability of the recombinant human prion protein."
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: "some hereditary forms of prion disease cannot be rationalized using the concept of mutation-induced thermodynamic destabilization of the cellular prion protein"
    explanation: >-
      The paper set out to test this exact hypothesis for the FFI (M129/D178N), GSS
      (P102L) and familial CJD (E200K) variants and concluded against it. D178N could not
      even be assayed because it aggregated; P102L was indistinguishable from wild-type
      and E200K only very slightly destabilized.
  - reference: PMID:10079068
    reference_title: "Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein."
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: "These data suggest that destabilization of PrPC is neither a general mechanism underlying the formation of PrPSc nor the basis of disease phenotypes in inherited human TSEs."
    explanation: >-
      Independent replication across all eight disease-associated substitutions in the
      structured C-terminal domain: five destabilize it and three do not, and the
      stabilities do not track disease phenotype.
  - reference: PMID:10360358
    reference_title: "Extremely rapid folding of the C-terminal domain of the prion protein without kinetic intermediates."
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: "propagation of the abnormal, oligomeric prion protein PrP(Sc), which is supposed to be the causative agent of transmissible spongiform encephalopathies, is unlikely to follow a mechanism where kinetic folding intermediates of PrP(C) are a source of PrP(Sc) subunits"
    explanation: >-
      Refutes the kinetic half of the hypothesis specifically. Stopped-flow folding of the
      structured domain has a half-life of about 170 microseconds with no detectable
      intermediates, so a populated folding intermediate is not available as the PrP-Sc
      precursor. Species/construct caveat: measured on murine mPrP(121-231) carrying an
      engineered F175W fluorescence reporter - not human PrP and not the D178N-129M
      haplotype - so the argument is a cross-species extrapolation resting on the
      conservation of the C-terminal globular fold between mouse and human PrP. The
      authors show the reporter variant has "the same overall structure and stability as
      wild-type mPrP(121-231)", which addresses the construct but not the species step.
  notes: >-
    Deprecating this hypothesis does not resolve the mechanism - it only removes a wrong
    answer. How the D178N-129M haplotype actually confers conversion propensity, and why
    the same substitution with 129V yields familial CJD instead, remains open; see the
    strain-identity knowledge-gap discussion on this entry.

pathophysiology:
- name: PRNP D178N-129M Germline Allele
  biological_scale: MOLECULAR
  description: >-
    A heterozygous PRNP p.Asp178Asn allele, carried in cis with methionine at codon
    129, is present from conception in every cell. The cis-phase is part of the lesion:
    the same amino-acid substitution with valine at codon 129 produces a different
    disease (familial CJD), so the pathogenic unit is the haplotype, not the codon-178
    change alone.
  genes:
  - preferred_term: PRNP
    term:
      id: hgnc:9449
      label: PRNP
  downstream:
  - target: Acquisition of a Conversion-Prone PrP-C State
  evidence:
  - reference: PMID:1439789
    reference_title: "Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Met129, Asn178 allele segregated with FFI in all 15 affected members of five kindreds whereas the Val129, Asn178 allele segregated with the familial CJD subtype in all 15 affected members of six kindreds."
    explanation: Names the specific pathogenic haplotype that segregates with FFI.
- name: Acquisition of a Conversion-Prone PrP-C State
  biological_scale: MOLECULAR
  description: >-
    The D178N substitution, in cis with 129M, renders PrP-C prone to adopting the
    misfolded, self-templating conformer that seeds propagation. Recombinant human PrP
    carrying the FFI M129/D178N haplotype is markedly aggregation-prone: unlike the
    GSS (P102L) and familial CJD (E200K) variants, which are recovered soluble, the
    D178N protein partitions into inclusion bodies. This is a gain of toxic
    conformation, not a loss of PrP function.
  notes: >-
    Curation note on what this node deliberately does NOT claim. An earlier revision
    asserted that D178N lowers the "thermodynamic and kinetic barrier" separating the
    native alpha-helical fold from beta-sheet-rich conformers. That wording was removed:
    it states as mechanism a hypothesis the primary literature has tested and rejected.
    The refuting evidence is recorded at disease level as the DEPRECATED
    `native_state_destabilization` hypothesis (PMID:9813003, PMID:10079068,
    PMID:10360358) rather than here, so the refutation stays attached to the claim it
    refutes. This node is therefore scoped to the conversion and aggregation propensity
    that is actually observed; the mechanism by which the D178N-129M haplotype confers
    it remains open - see the strain-identity knowledge-gap discussion.
  biological_processes:
  - preferred_term: protein folding
    term:
      id: GO:0006457
      label: protein folding
    modifier: ABNORMAL
  downstream:
  - target: Template-Directed Conversion of PrP-C to FFI-Type PrP-Sc
  evidence:
  - reference: PMID:9813003
    reference_title: "Familial mutations and the thermodynamic stability of the recombinant human prion protein."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "whereas the D178N variant aggregated into inclusion bodies"
    explanation: >-
      Recombinant human PrP(90-231) carrying the FFI M129/D178N haplotype partitions into
      inclusion bodies, where the P102L and E200K variants are recovered soluble from the
      same expression system - so aggregation propensity distinguishes this haplotype
      from the other familial variants. Tagged PARTIAL rather than SUPPORT deliberately:
      inclusion-body formation in E. coli is an aggregation observation and a common
      expression artifact, not a clean proxy for self-templating conversion propensity in
      vivo, and the authors draw no such inference themselves - they report it only as
      the reason D178N could not be assayed.
- name: Template-Directed Conversion of PrP-C to FFI-Type PrP-Sc
  biological_scale: MOLECULAR
  description: >-
    The autocatalytic core of the disease: a misfolded PrP molecule recruits and
    refolds native PrP-C, so that the conformation itself acts as the replicating
    template. In FFI the resulting protease-resistant core is a 19 kDa (type 2)
    fragment with marked underrepresentation of the unglycosylated glycoform - a
    molecular signature distinct from the 21 kDa fragment of sporadic and other
    inherited prion diseases. Inoculation of FFI brain extract into chimeric
    human-mouse PrP transgenic mice reproduces the 19 kDa fragment, establishing that
    conformation, not sequence, carries the strain information.
  biological_processes:
  - preferred_term: protein homooligomerization
    term:
      id: GO:0051260
      label: protein homooligomerization
    modifier: INCREASED
  - preferred_term: protein refolding
    term:
      id: GO:0042026
      label: protein refolding
    modifier: INCREASED
  downstream:
  - target: Regionally Selective PrP-Sc Accumulation in Gray Matter
  evidence:
  - reference: PMID:8953038
    reference_title: "Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "of PrPSc after deglycosylation has a size of 19 kilodaltons, whereas that from"
    explanation: Establishes the 19 kDa FFI-specific protease-resistant PrP fragment.
  - reference: PMID:8953038
    reference_title: "Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "chimeric human-mouse PrP gene about 200 days after inoculation and induced"
    explanation: Transmission to transgenic mice shows the conformer is a self-templating, transmissible strain.
  - reference: PMID:8953038
    reference_title: "Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "formation of the 19-kilodalton PrPSc fragment"
    explanation: The inoculated mice generate the FFI-type 19 kDa fragment rather than the 21 kDa CJD fragment.
- name: Regionally Selective PrP-Sc Accumulation in Gray Matter
  biological_scale: TISSUE
  description: >-
    Protease-resistant PrP accumulates in gray matter but not white matter or
    peripheral organs, and its distribution is broader than the histological lesions:
    lesions appear only where a critical amount of the abnormal protein has
    accumulated. The kinetics are region-specific - the mediodorsal thalamic nucleus
    and brainstem carry comparable amounts regardless of disease duration, whereas
    neocortical accumulation rises with duration, so the process spreads over time.
  locations:
  - preferred_term: medial dorsal nucleus of thalamus
    term:
      id: UBERON:0002739
      label: medial dorsal nucleus of thalamus
  - preferred_term: anterior nuclear group of thalamus
    term:
      id: UBERON:0002788
      label: anterior nuclear group
  - preferred_term: inferior olivary complex
    term:
      id: UBERON:0002127
      label: inferior olivary complex
  downstream:
  - target: Preferential Thalamic Neuronal Loss and Astrogliosis
  evidence:
  - reference: PMID:7611720
    reference_title: "Regional distribution of protease-resistant prion protein in fatal familial insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "was detected in gray matter but not in white matter and peripheral organs"
    explanation: Establishes the gray-matter-restricted distribution of protease-resistant PrP in FFI.
  - reference: PMID:7611720
    reference_title: "Regional distribution of protease-resistant prion protein in fatal familial insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "it was more widespread in the subjects with a longer clinical"
    explanation: The accumulation spreads within the brain as the disease progresses.
  - reference: PMID:9222180
    reference_title: "Cerebral metabolism in fatal familial insomnia: relation to duration, neuropathology, and distribution of protease-resistant prion protein."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PrPres formation is the cause of neuronal dysfunction in prion diseases."
    explanation: Links PrPres accumulation causally to neuronal dysfunction in prion disease.
- name: Preferential Thalamic Neuronal Loss and Astrogliosis
  biological_scale: TISSUE
  description: >-
    The defining lesion: marked neuronal depletion and astrocytic gliosis concentrated
    in the mediodorsal and anteroventral thalamic nuclei, with inferior olivary
    hypertrophy and only limited cortical spongiosis. The mediodorsal nucleus appears
    intrinsically more vulnerable - it sustains severe neuronal loss at relatively
    moderate PrP-Sc burden - which is why FFI is a thalamic disease rather than a
    diffuse encephalopathy.
  cell_types:
  - preferred_term: thalamic projection neuron
    term:
      id: CL:0000679
      label: glutamatergic neuron
  - preferred_term: reactive astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: astrocyte activation
    term:
      id: GO:0048143
      label: astrocyte activation
    modifier: INCREASED
  - preferred_term: neuron apoptotic process
    term:
      id: GO:0051402
      label: neuron apoptotic process
    modifier: INCREASED
  locations:
  - preferred_term: medial dorsal nucleus of thalamus
    term:
      id: UBERON:0002739
      label: medial dorsal nucleus of thalamus
  downstream:
  - target: Collapse of Thalamocortical Sleep Oscillation
  - target: Loss of Thalamolimbic Autonomic Restraint
  evidence:
  - reference: PMID:9669701
    reference_title: "Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "marked neuronal loss and gliosis in the thalamus, especially the medio-dorsal"
    explanation: Establishes the thalamic neuronal loss and gliosis that define FFI neuropathology.
  - reference: PMID:9669701
    reference_title: "Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "and anterior-ventral nuclei, olivary hypertrophy and some spongiosis of the"
    explanation: Names the anteroventral nucleus and olivary hypertrophy, with only some cortical spongiosis.
  - reference: PMID:7611720
    reference_title: "Regional distribution of protease-resistant prion protein in fatal familial insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the mediodorsal thalamic nucleus, however, a severe neuronal loss"
    explanation: The mediodorsal nucleus shows severe loss at moderate PrPres burden, indicating selective vulnerability.
- name: Collapse of Thalamocortical Sleep Oscillation
  biological_scale: ORGANISM
  description: >-
    Destruction of thalamic relay and reticular circuitry abolishes the thalamocortical
    oscillations that generate sleep spindles, K-complexes, and slow-wave sleep. The
    result is not ordinary insomnia but a failure to build sleep: spindles and
    K-complexes disappear early, NREM sleep is eventually abolished, and only brief
    residual REM periods without atonia persist, intruding into wakefulness as enacted
    dreams. FFI is the clinical experiment that implicated the thalamus as necessary
    for sleep generation.
  biological_processes:
  - preferred_term: circadian sleep/wake cycle
    term:
      id: GO:0042745
      label: circadian sleep/wake cycle
    modifier: DECREASED
  - preferred_term: regulation of circadian sleep/wake cycle
    term:
      id: GO:0042749
      label: regulation of circadian sleep/wake cycle
    modifier: ABNORMAL
  evidence:
  - reference: PMID:7607093
    reference_title: "Sleep-wake cycle abnormalities in fatal familial insomnia. Evidence of the role of the thalamus in sleep regulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "an early reduction in sleep spindles and K complexes, and a drastic reduction in"
    explanation: Documents early loss of the thalamocortical spindle/K-complex signature.
  - reference: PMID:7607093
    reference_title: "Sleep-wake cycle abnormalities in fatal familial insomnia. Evidence of the role of the thalamus in sleep regulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "abolition of NREM sleep and persistence of only brief residual periods of REM"
    explanation: Shows complete NREM abolition with residual REM in the short-course cases.
  - reference: PMID:12849238
    reference_title: "Familial and sporadic fatal insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Intriguing clinicopathological correlations in FFI and SFI suggest a role for"
    explanation: Frames the thalamolimbic system as the sleep-regulatory structure implicated by FFI.
- name: Loss of Thalamolimbic Autonomic Restraint
  biological_scale: ORGANISM
  description: >-
    Loss of thalamolimbic output releases sympathetic outflow, producing the sustained
    autonomic overactivity of FFI - tachycardia, hypertension, hyperhidrosis, and
    hyperthermia. Heart-rate-variability work shows the picture is not purely
    sympathetic excitation: parasympathetic (vagal) indices are also reduced relative
    to controls and to CJD, so cardiovascular dysautonomia reflects combined
    sympathetic activation and parasympathetic failure.
  biological_processes:
  - preferred_term: regulation of heart rate
    term:
      id: GO:0002027
      label: regulation of heart rate
    modifier: ABNORMAL
  evidence:
  - reference: PMID:12849238
    reference_title: "Familial and sporadic fatal insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both disorders have clinical features of disrupted sleep (loss of sleep spindles and slow-wave sleep and enacted dreams during rapid-eye-movement sleep), autonomic hyperactivation, and motor abnormalities (myoclonus, ataxia, dysarthria, dysphagia, and pyramidal signs)."
    explanation: Autonomic hyperactivation is a core feature of the FFI phenotype.
  - reference: PMID:36472576
    reference_title: "Dysfunction of the cardiac parasympathetic system in fatal familial insomnia: a heart rate variability study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cardiovascular dysautonomia in FFI may be partly attributable to"
    explanation: HRV evidence that parasympathetic dysfunction contributes, not sympathetic overactivity alone.
  - reference: PMID:36472576
    reference_title: "Dysfunction of the cardiac parasympathetic system in fatal familial insomnia: a heart rate variability study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "parasympathetic abnormalities, not just sympathetic activation"
    explanation: States explicitly that parasympathetic abnormality is part of FFI dysautonomia.

phenotypes:
- category: Neurological
  name: Progressive insomnia
  description: >-
    The hallmark manifestation: subacute, relentlessly progressive loss of sleep that
    is demonstrable on polysomnography as loss of sleep spindles and slow-wave sleep
    rather than as subjective sleeplessness alone.
  phenotype_term:
    preferred_term: Insomnia
    term:
      id: HP:0100785
      label: Insomnia
    clinical_course: PROGRESSIVE
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:1346338
    reference_title: "Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "progressive insomnia, dysautonomia, and motor signs"
    explanation: Progressive insomnia is the defining clinical triad element in the original FFI description.
  - reference: PMID:12849238
    reference_title: "Familial and sporadic fatal insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "loss of sleep spindles and slow-wave sleep and enacted dreams"
    explanation: Specifies the polysomnographic character of the sleep loss.
  - reference: PMID:7607093
    reference_title: "Sleep-wake cycle abnormalities in fatal familial insomnia. Evidence of the role of the thalamus in sleep regulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "impairment of sleep-wake regulation is a consistent distinctive feature of FFI"
    explanation: >-
      Frequency anchor for VERY_FREQUENT: "consistent distinctive feature" is a
      qualitative universal-class statement, mapping to the 80-100% band.
- category: Neurological
  name: Loss of sleep spindles and K-complexes
  description: >-
    Early and consistent polysomnographic abnormality; sleep-onset EEG grapho-elements
    generated by thalamocortical circuitry disappear, followed by loss of cyclic sleep
    organization and drastic reduction of total sleep time.
  phenotype_term:
    preferred_term: Abnormal sleep architecture on polysomnography
    term:
      id: HP:0002360
      label: Sleep disturbance
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:7607093
    reference_title: "Sleep-wake cycle abnormalities in fatal familial insomnia. Evidence of the role of the thalamus in sleep regulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients showed an early reduction in sleep spindles and K complexes"
    explanation: >-
      Frequency anchor for VERY_FREQUENT: all 6 patients in the longitudinal
      polygraphic series showed early spindle and K-complex reduction. VERY_FREQUENT
      rather than OBLIGATE is the conservative reading at n=6.
  - reference: PMID:7607093
    reference_title: "Sleep-wake cycle abnormalities in fatal familial insomnia. Evidence of the role of the thalamus in sleep regulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "total sleep time and disruption of the cyclic sleep organization"
    explanation: Documents reduced total sleep time and loss of cyclic sleep organization on 24-hour polygraphy.
  - reference: PMID:16399807
    reference_title: "Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "analysis disclosed an impaired thalamic sleep spindle formation"
    explanation: Impaired spindle formation is detectable even pre-symptomatically.
- category: Neurological
  name: Oneiric stupor with enacted dreams
  description: >-
    Episodes in which brief residual REM sleep without atonia intrudes on wakefulness,
    so the patient enacts dream content while apparently awake - particularly prominent
    in codon-129 methionine homozygotes.
  phenotype_term:
    preferred_term: REM sleep behavior disorder
    term:
      id: HP:5200291
      label: REM sleep behavior disorder
  subtype: 129MM
  evidence:
  - reference: PMID:12849238
    reference_title: "Familial and sporadic fatal insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "during rapid-eye-movement sleep), autonomic hyperactivation, and motor"
    explanation: Enacted dreams during REM sleep are part of the core FFI sleep phenotype.
  - reference: PMID:9669701
    reference_title: "Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "oneiric episodes, insomnia and dysautonomia at onset, whereas heterozygotes"
    explanation: Oneiric episodes are prominent at onset in codon-129 methionine homozygotes.
- category: Autonomic
  name: Dysautonomia
  description: >-
    Sustained autonomic dysfunction with sympathetic overactivity, present from early
    in the course; heart-rate-variability studies additionally show reduced
    parasympathetic (vagal) modulation.
  phenotype_term:
    preferred_term: Abnormal autonomic nervous system physiology
    term:
      id: HP:0012332
      label: Abnormal autonomic nervous system physiology
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:1346338
    reference_title: "Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "progressive insomnia, dysautonomia, and motor signs"
    explanation: Dysautonomia is one of the three defining clinical elements of FFI.
  - reference: PMID:9669701
    reference_title: "Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "disturbances of the wake-sleep cycle, dysautonomia and somatomotor"
    explanation: Names dysautonomia as one of the three characterizing feature groups of FFI.
  - reference: PMID:36472576
    reference_title: "Dysfunction of the cardiac parasympathetic system in fatal familial insomnia: a heart rate variability study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "sympathetic hyperactivity with preserved parasympathetic activity has been extensively recognized in fatal familial insomnia (FFI)"
    explanation: >-
      Establishes that sympathetic hyperactivity is the extensively recognized
      autonomic picture in FFI. The assumption of preserved parasympathetic activity
      stated here is what this study then challenges (see the pathophysiology node).
- category: Autonomic
  name: Tachycardia
  description: Persistently elevated heart rate with reduced beat-to-beat variability.
  phenotype_term:
    preferred_term: Tachycardia
    term:
      id: HP:0001649
      label: Tachycardia
  evidence:
  - reference: PMID:36472576
    reference_title: "Dysfunction of the cardiac parasympathetic system in fatal familial insomnia: a heart rate variability study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "higher heart rate with a lower amplitude of oscillations"
    explanation: Quantitative HRV evidence of persistent tachycardia with blunted oscillation in FFI.
- category: Autonomic
  name: Hyperhidrosis
  description: Episodic or sustained excessive sweating as part of sympathetic overactivity.
  phenotype_term:
    preferred_term: Hyperhidrosis
    term:
      id: HP:0000975
      label: Hyperhidrosis
  notes: >-
    Sweating is a standard component of the documented FFI sympathetic
    hyperactivation, but no quotable FFI-specific abstract naming hyperhidrosis was
    found; per the project evidence SOP the claim is recorded here rather than
    attached to a snippet that does not mention sweating. The general dysautonomia
    phenotype above carries the evidence.
- category: Neurological
  name: Myoclonus
  phenotype_term:
    preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  evidence:
  - reference: PMID:12849238
    reference_title: "Familial and sporadic fatal insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "abnormalities (myoclonus, ataxia, dysarthria, dysphagia, and pyramidal signs)"
    explanation: Myoclonus is listed among the characteristic motor abnormalities of FFI.
- category: Neurological
  name: Ataxia
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:12849238
    reference_title: "Familial and sporadic fatal insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "abnormalities (myoclonus, ataxia, dysarthria, dysphagia, and pyramidal signs)"
    explanation: Ataxia is a characteristic motor abnormality in FFI.
  - reference: PMID:9669701
    reference_title: "Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "showed ataxia and dysarthria at onset, earlier sphincter loss and epileptic"
    explanation: Ataxia is the typical presenting motor sign in codon-129 heterozygotes.
- category: Neurological
  name: Dysarthria
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:12849238
    reference_title: "Familial and sporadic fatal insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "abnormalities (myoclonus, ataxia, dysarthria, dysphagia, and pyramidal signs)"
    explanation: Dysarthria is a characteristic motor abnormality in FFI.
- category: Gastrointestinal
  name: Dysphagia
  description: >-
    Swallowing difficulty appearing as the disease advances, driving aspiration risk
    and contributing to terminal decline.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:12849238
    reference_title: "Familial and sporadic fatal insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "abnormalities (myoclonus, ataxia, dysarthria, dysphagia, and pyramidal signs)"
    explanation: Dysphagia is listed among the motor abnormalities of FFI.
- category: Neurological
  name: Spasticity and pyramidal signs
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:9669701
    reference_title: "Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "manifestations (myoclonus, ataxia, dysarthria, spasticity)"
    explanation: Spasticity is listed among the somatomotor manifestations of FFI.
- category: Neurological
  name: Impaired attention and vigilance
  description: >-
    The earliest cognitive change in FFI. Formal neuropsychological testing of seven
    patients from two kindreds identified impairment of attention and vigilance as the
    first deficit, consistent with loss of thalamic arousal-gating rather than cortical
    degeneration.
  phenotype_term:
    preferred_term: Short attention span
    term:
      id: HP:0000736
      label: Short attention span
  evidence:
  - reference: PMID:8780067
    reference_title: "Fatal familial insomnia: behavioral and cognitive features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "early impairment of attention and vigilance"
    explanation: Attention and vigilance impairment is the earliest neuropsychological deficit in FFI.
- category: Neurological
  name: Memory impairment
  description: >-
    Working-memory-predominant memory deficits with impaired temporal ordering of
    events - a thalamic-amnestic profile rather than the storage failure of cortical
    dementia.
  phenotype_term:
    preferred_term: Memory impairment
    term:
      id: HP:0002354
      label: Memory impairment
  evidence:
  - reference: PMID:8780067
    reference_title: "Fatal familial insomnia: behavioral and cognitive features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "memory deficits, mainly of the working memory"
    explanation: Documents the working-memory-predominant memory deficit in FFI.
  - reference: PMID:8780067
    reference_title: "Fatal familial insomnia: behavioral and cognitive features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "impairment of temporal ordering of events"
    explanation: Impaired temporal ordering accompanies the memory deficit.
- category: Neurological
  name: Progressive confusional state
  description: >-
    A progressive dream-like (oneiric) confusional state is the terminal cognitive
    picture. Importantly, the FFI neuropsychological syndrome was shown to be distinct
    from the cortical and subcortical dementias and from Wernicke-Korsakoff syndrome -
    so FFI is deliberately NOT curated here as HP:0000726 Dementia, even though
    GeneReviews describes "cognitive difficulties" generically across genetic prion
    disease. The finding challenged the concept of thalamic dementia.
  phenotype_term:
    preferred_term: Confusion
    term:
      id: HP:0001289
      label: Confusion
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:8780067
    reference_title: "Fatal familial insomnia: behavioral and cognitive features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a progressive dream-like state with"
    explanation: Names the progressive dream-like confusional state as the FFI cognitive endpoint.
  - reference: PMID:8780067
    reference_title: "Fatal familial insomnia: behavioral and cognitive features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "that is distinct from the cortical and subcortical"
    explanation: Basis for not classifying the FFI cognitive syndrome as a classical dementia.
- category: Neurological
  name: Bilateral tonic-clonic seizure
  description: >-
    Generalized seizures reported specifically in codon-129 methionine/valine
    heterozygotes, in keeping with their more extensive cortical involvement.
  phenotype_term:
    preferred_term: Bilateral tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
  subtype: 129MV
  evidence:
  - reference: PMID:9669701
    reference_title: "Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "showed ataxia and dysarthria at onset, earlier sphincter loss and epileptic"
    explanation: Epileptic grand mal seizures were observed in the codon-129 heterozygous group.
- category: Genitourinary
  name: Urinary incontinence
  description: >-
    Sphincter control is lost earlier in codon-129 heterozygotes than in homozygotes.
  phenotype_term:
    preferred_term: Urinary incontinence
    term:
      id: HP:0000020
      label: Urinary incontinence
  subtype: 129MV
  evidence:
  - reference: PMID:9669701
    reference_title: "Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "showed ataxia and dysarthria at onset, earlier sphincter loss and epileptic"
    explanation: Earlier sphincter loss characterizes the codon-129 heterozygous subtype.
- category: Neurological
  name: Progressive neurologic deterioration
  description: >-
    The course is continuously progressive rather than relapsing, ending in an
    akinetic, mute, fully dependent state.
  phenotype_term:
    preferred_term: Progressive neurologic deterioration
    term:
      id: HP:0002344
      label: Progressive neurologic deterioration
  evidence:
  - reference: PMID:20301407
    reference_title: "Genetic Prion Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The disease course ranges from a few months in gCJD"
    explanation: GeneReviews describes the short, progressive course of FFI and gCJD.

biochemical:
- name: Protease-resistant PrP (PrP-Sc) type 2, 19 kDa
  notes: >-
    The FFI molecular signature on Western blot of brain tissue: a protease-resistant
    PrP core of relative molecular mass 19 kDa (type 2), with marked
    underrepresentation of the unglycosylated glycoform relative to the di- and
    monoglycosylated forms. This distinguishes FFI both from other prion diseases
    (21 kDa, type 1) and from sporadic fatal insomnia (19 kDa but without the
    glycoform skew). It is a post-mortem or biopsy brain-tissue finding, not a
    clinically accessible fluid biomarker.
  presence: INCREASED
  specificity: HIGH
  evidence:
  - reference: PMID:10371520
    reference_title: "A subtype of sporadic prion disease mimicking fatal familial insomnia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the relative molecular mass of 19 kDa, corresponding to the so-called type 2,"
    explanation: Defines the 19 kDa type-2 PrP-Sc that identifies FFI.
  - reference: PMID:1346338
    reference_title: "Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Protease-resistant PrP was found in both patients with fatal familial"
    explanation: Original demonstration of protease-resistant PrP in FFI brain.
- name: CSF total tau
  notes: >-
    Elevated CSF total tau (threshold >1400 pg/mL in the Chinese national
    surveillance series) is found in more than half of FFI cases. It is notable as
    the one widely available CSF marker that is usually informative in FFI, in
    contrast to 14-3-3 and RT-QuIC, which both underperform in D178N. It is a marker
    of neuronal injury rather than a prion-specific test, so it supports but does not
    establish the diagnosis.
  presence: INCREASED
  specificity: LOW
  evidence:
  - reference: PMID:34487324
    reference_title: "Genetic Prion Disease: Insight from the Features and Experience of China National Surveillance for Creutzfeldt-Jakob Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Increased CSF tau was found in more than half of FFI and T188K gCJD cases"
    explanation: Quantifies elevated CSF total tau in the majority of FFI cases.
  - reference: PMID:34487324
    reference_title: "Genetic Prion Disease: Insight from the Features and Experience of China National Surveillance for Creutzfeldt-Jakob Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Increased CSF tau was unusual in P102L GSS but was quite common in the other subtypes of gPrD, including D178N FFI"
    explanation: Confirms CSF tau elevation is common specifically in D178N FFI.

diagnosis:
- name: PRNP sequencing with codon-129 phasing
  description: >-
    Diagnosis is established by identifying the heterozygous PRNP c.532G>A (D178N)
    pathogenic variant. Because the same substitution causes familial CJD when carried
    in cis with 129V, the codon-129 allele on the mutant chromosome must be
    determined - genotyping codon 129 without phasing is insufficient. Chromosomal
    microarray, karyotype, and repeat-expansion testing have no role.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  evidence:
  - reference: PMID:20301407
    reference_title: "Genetic Prion Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "proband with suggestive findings and a heterozygous PRNP pathogenic variant"
    explanation: GeneReviews diagnostic criterion for genetic prion disease including FFI.
  - reference: PMID:1439789
    reference_title: "Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "segregated with FFI in all 15 affected members of five kindreds whereas the"
    explanation: Justifies why codon-129 phasing is diagnostically necessary rather than optional.
- name: Polysomnography
  description: >-
    Polysomnography measures the defining physiological lesion directly: loss of sleep
    spindles and K-complexes, drastic reduction in total sleep time, loss of cyclic
    sleep organization, and eventual abolition of NREM sleep with residual REM without
    atonia. It is the most informative ancillary test in FFI.
  diagnosis_term:
    preferred_term: polysomnography
    term:
      id: NCIT:C114185
      label: Polysomnography
  evidence:
  - reference: PMID:7607093
    reference_title: "Sleep-wake cycle abnormalities in fatal familial insomnia. Evidence of the role of the thalamus in sleep regulation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "an early reduction in sleep spindles and K complexes, and a drastic reduction in"
    explanation: Polysomnography demonstrates the characteristic FFI sleep abnormalities.
- name: FDG-PET showing thalamic hypometabolism
  description: >-
    18F-FDG PET consistently shows severely reduced glucose utilization in the thalamus
    with mild cingulate hypometabolism - the functional hallmark of FFI. Cortical
    involvement is broader in patients with a longer course. Hypometabolism extends
    beyond the histopathological lesions and correlates with PrPres distribution.
  diagnosis_term:
    preferred_term: positron emission tomography procedure
    term:
      id: NCIT:C17007
      label: Positron Emission Tomography
  evidence:
  - reference: PMID:9222180
    reference_title: "Cerebral metabolism in fatal familial insomnia: relation to duration, neuropathology, and distribution of protease-resistant prion protein."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hypometabolism of the thalamus and cingulate cortex is the"
    explanation: Thalamic plus cingulate hypometabolism is described as the hallmark of FFI.
  - reference: PMID:8255458
    reference_title: "[18F]FDG PET in fatal familial insomnia: the functional effects of thalamic lesions."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "widespread brain hypometabolism involving the majority of cortical structures,"
    explanation: Documents the more widespread cortical hypometabolism seen in clinically complex cases.
  - reference: PMID:9222180
    reference_title: "Cerebral metabolism in fatal familial insomnia: relation to duration, neuropathology, and distribution of protease-resistant prion protein."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hypometabolism was more widespread in the MET/VAL129 group"
    explanation: Relates the extent of hypometabolism to codon-129 genotype and disease duration.
- name: Pre-symptomatic thalamic hypometabolism in mutation carriers
  description: >-
    Serial FDG-PET and polysomnography in asymptomatic D178N carriers were normal 21 to
    63 months before onset, but selective thalamic hypometabolism with impaired spindle
    formation appeared about 13 months before clinical presentation - placing the start
    of measurable neurodegeneration in a narrow 13-21 month pre-symptomatic window.
    This defines the therapeutic window for any preventive intervention.
  diagnosis_term:
    preferred_term: positron emission tomography procedure
    term:
      id: NCIT:C17007
      label: Positron Emission Tomography
  evidence:
  - reference: PMID:16399807
    reference_title: "Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "selective hypometabolism was detected in the thalamus while spectral-EEG"
    explanation: Pre-symptomatic thalamic hypometabolism detected 13 months before onset.
  - reference: PMID:16399807
    reference_title: "Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "FFI begins in the thalamus between 13 and 21 months before the clinical"
    explanation: Establishes the pre-symptomatic onset window of the neurodegenerative process.
- name: CSF RT-QuIC (low sensitivity in D178N FFI)
  description: >-
    Real-time quaking-induced conversion is the modern seeding assay for prion
    disease, but it performs worst in FFI of all the common genetic prion subtypes.
    In the Chinese national surveillance series the D178N group had the lowest
    RT-QuIC positivity rate of any subtype at 15.8%, against 63.6% for P102L GSS and
    a 32.3% overall rate. Clinically decisive point: a negative CSF RT-QuIC does NOT
    exclude FFI, and PRNP sequencing remains the diagnostic test.

    Curation note on the comparator: the source is internally inconsistent about which
    GSS allele carries the 63.6% rate - its abstract says P105L, its results and
    discussion sections say P102L. P102L is used here because it matches the body text
    and the quoted snippet. Do not "correct" this against the abstract.
  diagnosis_term:
    preferred_term: cerebrospinal fluid analysis
    term:
      id: NCIT:C173272
      label: CSF Analysis
  evidence:
  - reference: PMID:34487324
    reference_title: "Genetic Prion Disease: Insight from the Features and Experience of China National Surveillance for Creutzfeldt-Jakob Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The highest RT-QuIC positivity rate (63.6%) was in the P102L group and lowest (15.8%) in the D178N group"
    explanation: Quantifies the low RT-QuIC sensitivity in D178N FFI relative to other genetic prion subtypes.
- name: CSF 14-3-3 (frequently negative in D178N FFI)
  description: >-
    CSF 14-3-3, a classic surrogate marker of rapid neuronal injury in
    Creutzfeldt-Jakob disease, is frequently negative in FFI. Positivity concentrates
    in genetic CJD with C-terminal PRNP mutations (after amino acid 188) and is
    specifically not characteristic of P102L GSS or D178N FFI, so a negative result
    has no exclusionary value here.
  diagnosis_term:
    preferred_term: cerebrospinal fluid analysis
    term:
      id: NCIT:C173272
      label: CSF Analysis
  evidence:
  - reference: PMID:34487324
    reference_title: "Genetic Prion Disease: Insight from the Features and Experience of China National Surveillance for Creutzfeldt-Jakob Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CSF 14-3-3 showed high positivity rates, particularly in gCJD patients with a point mutation in the C-terminal (after aa 188), but not in P102L and D178N cases."
    explanation: Establishes that CSF 14-3-3 is not a reliable positive marker in D178N FFI.
- name: Brain MRI (low yield in D178N FFI)
  description: >-
    The sporadic-CJD MRI signature - cortical ribboning on DWI, caudate/putamen
    hyperintensity, and pulvinar/posterior-thalamic signal - is informative across
    most genetic prion subtypes but specifically not in FFI. Only 25.5% of D178N
    cases showed any such abnormality, versus 92.3% of P102L cases and a 66.0%
    overall rate, and all three individual MRI abnormalities were low in D178N. A
    normal or nonspecific MRI is therefore the expected finding in FFI.
  diagnosis_term:
    preferred_term: magnetic resonance imaging procedure
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  evidence:
  - reference: PMID:34487324
    reference_title: "Genetic Prion Disease: Insight from the Features and Experience of China National Surveillance for Creutzfeldt-Jakob Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI scanning is helpful for most types of gPrD with positivity rates similar to sCJD, except for D178N FFI"
    explanation: States explicitly that MRI is the exception - unhelpful - in D178N FFI.
  - reference: PMID:34487324
    reference_title: "Genetic Prion Disease: Insight from the Features and Experience of China National Surveillance for Creutzfeldt-Jakob Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "only 25.5% (12/47) of D178N cases showed such an abnormality"
    explanation: Quantifies the low MRI positivity rate in D178N FFI.
  - reference: PMID:34487324
    reference_title: "Genetic Prion Disease: Insight from the Features and Experience of China National Surveillance for Creutzfeldt-Jakob Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "all three MRI abnormalities in D178N FFI patients were clearly low"
    explanation: All three sporadic-CJD MRI abnormalities are individually low-yield in FFI.
- name: EEG (periodic sharp wave complexes essentially absent)
  description: >-
    The periodic sharp wave complexes that support a diagnosis of sporadic
    Creutzfeldt-Jakob disease are effectively absent in FFI: only 1 of 48 D178N cases
    showed PSWCs, against 48.5% of E200K genetic CJD cases. EEG in FFI is instead
    useful for spectral analysis of sleep architecture (see polysomnography), not for
    the classic periodic pattern.
  diagnosis_term:
    preferred_term: electroencephalography
    term:
      id: NCIT:C38054
      label: Electroencephalography
  evidence:
  - reference: PMID:34487324
    reference_title: "Genetic Prion Disease: Insight from the Features and Experience of China National Surveillance for Creutzfeldt-Jakob Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Only one out of 48 cases of D178N FFI showed PSWCs on the EEG"
    explanation: Quantifies the near-absence of the classic CJD periodic EEG pattern in FFI.

progression:
- notes: >-
    Onset is typically in the sixth decade (GeneReviews gives 50-60 years for genetic
    prion disease broadly), though reported FFI onsets span roughly 19 to 68 years. The
    course is continuously progressive and death follows within months to about three
    years. Duration is bimodal by the codon-129 genotype of the non-mutant allele:
    about 9 months in methionine homozygotes versus about 31 months in
    methionine/valine heterozygotes. In national surveillance data, FFI and GSS
    patients tend to present earlier than point-mutation genetic CJD patients.
  evidence:
  - reference: PMID:20301407
    reference_title: "Genetic Prion Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "ranges from 50 to 60 years"
    explanation: GeneReviews typical age at onset for genetic prion disease including FFI.
  - reference: PMID:9669701
    reference_title: "Clinical features of fatal familial insomnia: phenotypic variability in relation to a polymorphism at codon 129 of the prion protein gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients ran either a short (9.1 +/- 1.1 months) or a prolonged (30.8 +/-"
    explanation: Quantifies the bimodal disease duration by codon-129 genotype.
  - reference: PMID:34487324
    reference_title: "Genetic Prion Disease: Insight from the Features and Experience of China National Surveillance for Creutzfeldt-Jakob Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "insomnia (FFI) cases usually displayed clinical symptoms earlier than genetic"
    explanation: National surveillance data on relative age at onset of FFI versus genetic CJD.

treatments:
- name: Multidisciplinary supportive and palliative care
  description: >-
    No disease-modifying therapy exists. Management is supportive: sleep-symptom
    management, autonomic and cardiac monitoring, nutrition and swallowing assessment,
    fall prevention, physical/occupational/speech therapy, psychiatric and caregiver
    support, advance care planning, and palliative care. Sedatives may reduce distress
    but do not restore sleep architecture, and polypharmacy can worsen confusion,
    falls, and respiratory risk.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301407
    reference_title: "Genetic Prion Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Supportive care by a multidisciplinary team"
    explanation: GeneReviews recommends multidisciplinary supportive care as the mainstay of management.
  - reference: PMID:20301407
    reference_title: "Genetic Prion Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "genetic prion disease is available."
    explanation: GeneReviews confirms no treatment of the underlying cause is available.
- name: Close periodic surveillance
  description: >-
    Because progression is very rapid, GeneReviews recommends review by the
    multidisciplinary team approximately every 14 days to reassess symptomatic needs.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301407
    reference_title: "Genetic Prion Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "periodic monitoring by the multidisciplinary team is needed, typically every 14"
    explanation: GeneReviews surveillance interval for genetic prion disease.
- name: Genetic counseling and predictive testing
  description: >-
    Autosomal dominant risk counseling with a 50% transmission risk, predictive-testing
    protocols for at-risk adults that respect the right not to know, and reproductive
    options including preimplantation genetic testing. GeneReviews considers predictive
    testing of asymptomatic minors inappropriate for this adult-onset condition. The
    ethical weight of the right not to know is unusually prominent in FFI: the
    preventive doxycycline study was designed around participants' refusal to learn
    their own genotype, enrolling carriers and non-carriers together under a
    genotype-concealing scheme.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301407
    reference_title: "Genetic Prion Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Predictive testing in minors (i.e., testing of asymptomatic at-risk individuals younger than age 18 years) is considered inappropriate."
    explanation: GeneReviews addresses the appropriateness of predictive testing in minors.
  - reference: PMID:35737759
    reference_title: "Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "include both carriers of the FFI mutation (10 subjects), and non-carriers (15"
    explanation: The trial design that accommodated participants' wish not to learn their genotype.
- name: Doxycycline (preventive, investigational)
  description: >-
    Doxycycline was selected for pre-symptomatic prevention on the basis of preclinical
    anti-prion activity, good blood-brain-barrier penetration, and a known safety
    profile. In the preventive study, 10 D178N carriers over 42 years old received
    100 mg/day and 15 non-carriers received placebo under a genotype-concealing design,
    with incidence compared against a historical dataset over 10 years. The published
    material establishes feasibility and design, not proven prevention.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: doxycycline
      term:
        id: CHEBI:50845
        label: doxycycline
  evidence:
  - reference: PMID:25996399
    reference_title: "Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "doxycycline, an antibiotic with anti-prion activity"
    explanation: States the anti-prion rationale for doxycycline; preventive efficacy is unresolved, hence PARTIAL.
  - reference: PMID:25996399
    reference_title: "Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "over 42 y old will be treated with doxycycline (100 mg/die)"
    explanation: Documents the dose and eligible population in the preventive study.
  - reference: PMID:35737759
    reference_title: "Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "repurposing of doxycycline - an antibiotic with a known safety profile and"
    explanation: Describes the repurposing rationale; outcome data were not available at publication.

clinical_trials:
- name: NCT06153966
  phase: PHASE_I
  status: ACTIVE_NOT_RECRUITING
  description: >-
    PrProfile - a Phase 1/2a first-in-human study of intrathecal ION717, an antisense
    oligonucleotide that lowers PrP by degrading PRNP mRNA, in patients with prion
    disease. PrP lowering acts upstream of conformational conversion and is therefore
    mechanistically applicable to FFI.
  evidence:
  - reference: clinicaltrials:NCT06153966
    reference_title: "A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION717 in Patients With Prion Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717."
    explanation: The active PrP-lowering ASO programme relevant to genetic prion disease including FFI.

discussions:
- discussion_id: gap_ffi_thalamic_selectivity
  kind: KNOWLEDGE_GAP
  prompt: >-
    Why is the mediodorsal thalamic nucleus so selectively vulnerable in FFI, sustaining
    severe neuronal loss at only moderate PrP-Sc burden, when protease-resistant PrP is
    distributed far more widely across gray matter?
  rationale: >-
    Regional PrPres quantification shows accumulation is broader than the lesions, and
    that the mediodorsal nucleus is damaged at PrPres levels that leave other regions
    intact. Neither the 19 kDa strain conformation nor codon-129 phase explains why this
    particular nucleus is the primary target, so the cell-intrinsic determinant of
    thalamic vulnerability is unknown.
  attaches_to:
  - pathophysiology#Preferential Thalamic Neuronal Loss and Astrogliosis
  proposed_experiments:
  - experiment_id: exp_ffi_thalamic_vulnerability_spatial_omics
    name: Spatially resolved comparison of vulnerable versus resistant thalamic nuclei
    description: >-
      Perform cell-type-resolved spatial transcriptomics and proteomics on FFI autopsy
      thalamus, comparing the mediodorsal and anteroventral nuclei against thalamic
      nuclei that remain histologically intact in the same brains. Test whether
      baseline PRNP expression level, proteostatic capacity (chaperone and
      ubiquitin-proteasome components), or metabolic reserve tracks with regional
      vulnerability after adjusting for local PrPres burden.
  - experiment_id: exp_ffi_prelesional_knockin_mouse_thalamus
    name: Pre-lesional single-nucleus profiling of D178N-129M knock-in thalamus
    description: >-
      Profile thalamic nuclei of D178N-129M knock-in mice at time points before
      histological lesions or EEG change appear, to separate primary cell-intrinsic
      vulnerability from secondary injury response. A vulnerability signature present
      pre-lesionally and restricted to the mediodorsal nucleus would support a
      cell-intrinsic determinant.
- discussion_id: gap_ffi_prevention_window
  kind: KNOWLEDGE_GAP
  prompt: >-
    Can PrP-lowering therapy started inside the 13-21 month pre-symptomatic window
    prevent or delay clinical FFI, and what surrogate endpoint could demonstrate that?
  rationale: >-
    Serial FDG-PET places the start of measurable thalamic neurodegeneration 13-21
    months before onset, implying that intervention must be pre-symptomatic. But the
    preventive doxycycline study had to compare against a historical dataset precisely
    because no validated surrogate endpoint exists, and that gap now blocks efficient
    trials of the mechanistically stronger PrP-lowering agents.
  attaches_to:
  - pathophysiology#Template-Directed Conversion of PrP-C to FFI-Type PrP-Sc
  proposed_experiments:
  - experiment_id: exp_ffi_presymptomatic_surrogate_qualification
    name: Qualification of a composite pre-symptomatic FFI progression surrogate
    description: >-
      Follow a prospective cohort of D178N carriers with paired thalamic FDG-PET,
      quantitative spindle-density polysomnography, and plasma neurofilament light,
      anchored to observed clinical conversion. Test whether any single measure or
      composite changes monotonically across the 13-21 month pre-symptomatic window
      with enough effect size to power a prevention trial shorter than the 10-year
      historical-control design.
  - experiment_id: exp_ffi_presymptomatic_prnp_aso_biomarker_trial
    name: Biomarker-endpoint PRNP-lowering ASO trial in pre-symptomatic carriers
    description: >-
      Test intrathecal PRNP-lowering antisense oligonucleotide in pre-symptomatic D178N
      carriers using thalamic metabolic decline (with CSF PrP reduction as the
      target-engagement measure) as the primary endpoint rather than clinical
      conversion, pairing it with the genotype-concealing consent design that the
      doxycycline study showed to be acceptable to these families.
- discussion_id: gap_ffi_sfi_strain_identity
  kind: KNOWLEDGE_GAP
  prompt: >-
    If sporadic fatal insomnia is clinically and histopathologically near-identical to
    FFI and carries the same 19 kDa type-2 PrP-Sc, why does it lack the glycoform skew
    characteristic of FFI, and does that difference mean a distinct prion strain?
  rationale: >-
    Sporadic fatal insomnia patients are codon-129 methionine homozygotes without D178N,
    yet reproduce the FFI phenotype - implying the 19 kDa conformer, not the mutation,
    specifies the disease. The reproducible absence of unglycosylated-isoform
    underrepresentation is an unexplained molecular discrepancy that bears directly on
    whether glycosylation pattern is part of strain identity or a consequence of the
    mutant substrate.
  attaches_to:
  - pathophysiology#Template-Directed Conversion of PrP-C to FFI-Type PrP-Sc
  proposed_experiments:
  - experiment_id: exp_ffi_sfi_serial_transmission_strain_comparison
    name: Serial transmission comparison of FFI versus sporadic fatal insomnia isolates
    description: >-
      Inoculate humanized 129MM PrP transgenic mice with FFI and sporadic-fatal-insomnia
      brain isolates and compare incubation period, lesion profile, PrPres fragment
      size, and glycoform ratio across serial passages. Convergence of the glycoform
      ratio on serial passage would indicate the skew is substrate-determined rather
      than an intrinsic strain property.
  - experiment_id: exp_ffi_glycoform_substrate_dependence_pmca
    name: Cell-free conversion test of glycoform-skew substrate dependence
    description: >-
      Use protein misfolding cyclic amplification with mutant D178N-129M versus
      wild-type 129M PrP-C substrate, seeded with the same FFI-derived template, and
      measure whether the underrepresentation of the unglycosylated isoform requires the
      mutant substrate.
📚

References & Deep Research

References

1
PMID:20301407
Genetic Prion Disease
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Fatal Familial Insomnia: Disease Characteristics Research Report
Edison Scientific Literature 12 citations 2026-07-29T15:09:03.793327

Fatal Familial Insomnia: Disease Characteristics Research Report

Executive summary

Fatal familial insomnia (FFI) is an ultra-rare, autosomal-dominant genetic prion disease caused classically by PRNP c.532G>A, p.Asp178Asn (D178N), with methionine at polymorphic codon 129 on the mutant allele. It is characterized by progressive loss of physiologic sleep, dysautonomia, motor dysfunction, cognitive decline, and selective thalamic degeneration. Reported onset spans approximately 19–76 years, averaging about 51 years, and death usually occurs 6–36 months after clinical onset. No therapy has proven disease-modifying efficacy; management remains supportive, although PrP-lowering oligonucleotide programs now provide a plausible mechanism-directed strategy. (forloni2022preventivepharmacologicaltreatment pages 2-3, thune2023geneticvariantsassociated pages 1-2, thune2023geneticvariantsassociated pages 2-4)

The strongest recent FFI-specific evidence retrieved was a 2023 whole-exome study of onset modifiers and a 2022 report of the decade-long preventive doxycycline study. Because FFI is exceptionally rare, many phenotype frequencies, diagnostic-accuracy estimates, and treatment conclusions remain based on small cohorts, families, or extrapolation from other prion diseases rather than large prospective FFI studies. (forloni2022preventivepharmacologicaltreatment pages 3-5, thune2023geneticvariantsassociated pages 2-4, thune2023geneticvariantsassociated pages 8-9)

1. Disease information

Definition. FFI is an inherited transmissible spongiform encephalopathy in which pathogenic prion-protein conformers produce a rapidly progressive and fatal neurodegenerative syndrome dominated by sleep–wake disintegration, autonomic overactivity, and thalamic dysfunction. It is a disease-level entity assembled from aggregated family, cohort, neuropathology, and molecular resources—not an EHR-derived individual-patient phenotype. Individual case reports and clinical records constitute part of the underlying evidence.

Identifiers and synonyms. Commonly used identifiers are OMIM #600072 and Orphanet ORPHA:466; common names include fatal familial insomnia, familial fatal insomnia, FFI, and genetic fatal insomnia. The broader ICD-10-CM placement is generally A81.8, other atypical virus infections of the central nervous system, under which prion diseases are grouped. Exact current MONDO, MeSH, SNOMED CT, and ICD-11 leaf identifiers should be checked against the release used by the target knowledge base rather than inferred from literature text; the retrieved primary papers did not supply them.

A concise recent description states that FFI is a “rare autosomal-dominant inherited neurodegenerative prion disease” caused by D178N coupled to methionine at codon 129. (thune2023geneticvariantsassociated pages 1-2)

2. Etiology, risk, protection, and gene–environment interaction

Causal and genetic factors

The primary cause is a heterozygous germline PRNP p.Asp178Asn allele in cis with 129Met. The same D178N coding change associated with a different codon-129 haplotypic context can produce a genetic Creutzfeldt–Jakob disease phenotype, illustrating that the codon-129 background helps specify prion strain, molecular pathology, and phenotype. FFI is therefore not simply “D178N disease”; haplotype phasing matters. (thune2023geneticvariantsassociated pages 1-2, forloni2022preventivepharmacologicaltreatment pages 1-2)

The polymorphism on the non-mutant allele—129Met or 129Val—modifies onset, duration, and clinical expression, but does not reliably predict an individual’s onset. A 2023 WES study examined 25 D178N/129M patients: 12 women and 13 men, onset 19–68 years. Five had onset at 19–40 years and 20 at 42–68 years. Candidate later-onset modifiers included EXOC1L, SRSF11, MSANTD3, NR1H5P, and GNA13P1; the relevant variants were absent from the early-onset group. These remain exploratory associations requiring replication, not clinically validated protective alleles. (thune2023geneticvariantsassociated pages 2-4, thune2023geneticvariantsassociated pages 6-8, thune2023geneticvariantsassociated pages 8-9)

Penetrance and conventional risk factors

Penetrance is high and age-dependent. In one large Italian kindred, the summarized estimate was about 95%, based on 46 affected individuals and two apparent elderly nonpenetrant carriers. Family history and inheriting the pathogenic haplotype are the major established risks. There is no convincing evidence that sex, diet, smoking, alcohol, occupation, toxins, or routine lifestyle exposures materially determine disease occurrence. (forloni2022preventivepharmacologicaltreatment pages 2-3)

Protective and environmental factors

No validated genetic or environmental protective factor prevents FFI. The candidate later-onset variants above are hypotheses rather than actionable protection. No reproducible gene–environment interaction has been established. Ordinary insomnia or sleep deprivation does not cause FFI. FFI is genetic, not naturally acquired through infection or routine contact; standard prion precautions nevertheless apply to high-infectivity tissues and certain neurosurgical or laboratory procedures.

3. Phenotypes

The core syndrome is progressive and heterogeneous. Exact percentages should not be assigned unless tied to a defined cohort; the available recent evidence supports qualitative frequencies rather than population-wide rates.

  • Progressive insomnia and sleep–wake disintegration: hallmark, usually severe and progressive. Polysomnography may show loss of normal sleep architecture, poorly formed or absent spindles/K-complexes, reduced slow-wave and REM sleep, and intrusion of motor or dream-like behavior into wakefulness. Suggested HPO: Insomnia, Abnormal sleep pattern, Sleep-wake cycle disturbance.
  • Dysautonomia: common and often prominent—tachycardia, hypertension, hyperhidrosis, hyperthermia, altered respiratory rhythm, constipation, and endocrine/circadian disturbance. Suggested HPO: Autonomic nervous system dysfunction, Tachycardia, Hypertension, Hyperhidrosis, Abnormal body temperature.
  • Motor manifestations: ataxia, dysarthria, gait impairment, tremor, myoclonus, pyramidal signs, parkinsonism, and late akinetic-mutism-like states may occur. Suggested HPO: Cerebellar ataxia, Gait disturbance, Dysarthria, Myoclonus, Parkinsonism, Pyramidal sign.
  • Cognitive/behavioral manifestations: attentional and executive impairment, memory dysfunction, confusion, hallucinations, behavioral change, and progressive dementia. Suggested HPO: Cognitive impairment, Executive dysfunction, Hallucinations, Behavioral abnormality, Dementia.
  • Systemic/end-stage manifestations: weight loss, dysphagia, immobility, aspiration risk, infection, and complete dependence.

Recent literature summarizes the hallmarks as “progressive sleep loss, dementia, and autonomic nervous system failure.” The associated loss of independence, continuous autonomic symptoms, inability to obtain restorative sleep, progressive cognitive/motor disability, and terminal dependence imply profound quality-of-life effects, although validated FFI-specific EQ-5D, SF-36, or PROMIS datasets were not identified. (thune2023geneticvariantsassociated pages 1-2, forloni2022preventivepharmacologicaltreatment pages 1-2)

4. Genetic and molecular information

Gene: PRNP, encoding cellular prion protein, PrPᶜ. Canonical variant: NM_000311.5:c.532G>A; NP_000302.1:p.Asp178Asn, traditionally D178N. Laboratories must phase codon 129 because the disease-associated allele is D178N-129M. The variant is a germline missense allele with autosomal-dominant inheritance. It is expected to be absent or extraordinarily rare in population databases; current gnomAD release-specific counts should be queried directly before loading an allele-frequency field.

The pathogenic effect is best described as toxic conformational gain of function rather than simple PRNP haploinsufficiency. Mutant PrP favors conversion into misfolded, aggregation-prone, partially protease-resistant disease conformers that template additional PrP conversion. No recurrent causal chromosomal deletion, duplication, translocation, aneuploidy, somatic driver, or mitochondrial variant defines FFI.

Candidate modifier genes from the 2023 WES pilot are provisional. No clinically validated epigenetic modifier or disease-specific methylation signature is established. The authors identified 19 possible onset-associated variants and linked candidate genes to programmed cell death, caspase-mediated cytoskeletal cleavage, and apoptotic protein cleavage. (thune2023geneticvariantsassociated pages 6-8, thune2023geneticvariantsassociated pages 8-9)

5. Environmental and infectious information

No toxin, radiation, pollutant, occupation, diet, exercise pattern, tobacco exposure, alcohol use, bacterium, virus, fungus, or parasite is known to cause inherited FFI. The word prion denotes a protein-based transmissible agent, but familial disease arises endogenously from mutant PRNP. FFI is not considered contagious through social contact, caregiving, air, food, or body fluids. There is no vaccine indication.

6. Mechanism and pathophysiology

Causal chain

  1. Upstream trigger: germline D178N-129M changes PrP conformational stability.
  2. Prion conversion: mutant PrP forms or facilitates a disease-associated conformer capable of templated conversion and aggregation.
  3. Proteostasis and cellular stress: impaired protein handling, mitochondrial/ribosomal dysfunction, cytoskeletal stress, and apoptotic pathways emerge.
  4. Selective network injury: severe neuronal loss and astrogliosis preferentially affect anterior and mediodorsal thalamic nuclei, with inferior olivary and entorhinal involvement.
  5. Systems failure: thalamocortical sleep oscillations collapse; hypothalamic/autonomic and limbic-cognitive networks become dysregulated.
  6. Clinical syndrome: progressive agrypnia/insomnia, sympathetic overactivity, endocrine/circadian disturbance, ataxia and cognitive decline culminate in immobility and death. (forloni2022preventivepharmacologicaltreatment pages 2-3, thune2023geneticvariantsassociated pages 1-2)

Suggested GO terms include protein misfolding, protein aggregation, amyloid fibril formation, response to endoplasmic-reticulum stress, mitochondrial organization, oxidative phosphorylation, ribosome biogenesis, regulation of circadian rhythm, apoptotic process, caspase-mediated cleavage, neuron death, and astrocyte activation. Relevant cellular components are the neuronal plasma membrane, secretory pathway/ER, endolysosomal system, mitochondrion, ribosome, cytoskeleton, and extracellular protein aggregates.

The principal cell types are thalamic projection neurons, other glutamatergic neurons, inhibitory/GABAergic neurons, and reactive astrocytes; CL labels should include neuron, glutamatergic neuron, GABAergic neuron, and astrocyte. The 2023 modifier analysis implicated apoptosis-related biology, but causal roles for the candidate loci have not been experimentally established. (thune2023geneticvariantsassociated pages 6-8, thune2023geneticvariantsassociated pages 8-9)

Human terminal-brain proteomics and experimental cell-type translatomics suggest changes in oxidative phosphorylation, lysosomal/protein-export pathways, mitochondrial and translation machinery, circadian programs, and cytoskeletal responses. These data are mechanistically informative but do not yet constitute a validated diagnostic multi-omics signature. Single-cell and spatial-transcriptomic evidence specific to human FFI remains sparse.

7. Anatomical structures affected

The central nervous system is the primary organ system. The most characteristic lesions occur bilaterally in the anterior and mediodorsal/dorsomedial thalamic nuclei; the inferior olivary nuclei and entorhinal cortex may also be affected. The thalamic pattern is generally bilateral rather than lateralized. Suggested UBERON labels are brain, thalamus, mediodorsal nucleus of thalamus, anterior thalamic nuclear group, inferior olivary complex, entorhinal cortex, cerebral cortex, and hypothalamus. (forloni2022preventivepharmacologicaltreatment pages 2-3, thune2023geneticvariantsassociated pages 1-2)

Histologically, the dominant lesions are neuronal depletion and astrocytic gliosis. Secondary systemic involvement—cardiovascular, endocrine, thermoregulatory, respiratory, gastrointestinal, and nutritional—is primarily a consequence of autonomic-network failure and terminal neurologic disability rather than primary multiorgan proteinopathy.

8. Temporal development

FFI is usually adult-onset and insidious/subacute, although onset can occur in young adulthood or late life. Published ranges include 23–76 years, with an average near 51 years and a typical range of 36–62 years; the 2023 cohort included onset as early as 19. (thune2023geneticvariantsassociated pages 1-2, thune2023geneticvariantsassociated pages 2-4)

A useful clinical staging model is:

  1. Prodromal/early: worsening insomnia, altered sleep architecture, anxiety or autonomic activation.
  2. Intermediate: profound sleep–wake disorganization, dysautonomia, gait/motor impairment, cognitive and behavioral change.
  3. Advanced: severe dementia/confusion, dysphagia, ataxia or akinetic state, loss of ambulation and self-care.
  4. Terminal: near-continuous agrypnia, severe autonomic/metabolic instability, mutism/coma-like state, aspiration or infection, and death.

The course is continuously progressive, not relapsing-remitting; durable spontaneous or treatment-induced remission is not documented. Death generally follows within 6–36 months. Presymptomatic mutation carriers are the most rational intervention population because irreversible neuronal loss probably precedes overt disability. (thune2023geneticvariantsassociated pages 1-2)

9. Inheritance and population

Inheritance is autosomal dominant: each child of a heterozygous carrier has a 50% chance of inheriting the variant. Penetrance is high but age-dependent and not necessarily absolute; expressivity and age at onset are variable. Anticipation, consanguinity, and germline mosaicism are not established defining features. Founder kindreds exist, including the extensively studied Veneto/Treviso family; FFI has nevertheless been reported across multiple ancestries and geographic regions. (forloni2022preventivepharmacologicaltreatment pages 2-3, forloni2022preventivepharmacologicaltreatment pages 3-5)

The 2023 WES cohort’s near-equal sex distribution—12 women and 13 men—provides no evidence of strong sex bias. Reliable FFI-specific global incidence, point prevalence, and carrier frequency are unavailable. All human prion diseases together occur at roughly 1–2 cases per million person-years, but applying that figure to FFI would grossly overestimate FFI incidence. FFI represents only a very small familial subset.

10. Diagnostics

Recommended approach

  1. Recognize progressive insomnia/agrypnia plus dysautonomia, motor/cognitive decline, or a compatible pedigree.
  2. Obtain PRNP sequencing, explicitly testing D178N and determining/phasing codon 129.
  3. Use polysomnography, EEG, MRI, FDG-PET, autonomic testing, neuropsychology, and CSF studies to characterize disease and exclude mimics.
  4. Offer postmortem neuropathology where appropriate and consented.

Targeted single-gene sequencing is sufficient when the familial allele is known. A prion/rapid-dementia panel, WES, or WGS is useful for atypical or genetically unresolved cases, but WES/WGS must provide reliable PRNP coverage and codon-129 phasing. CMA, karyotyping, FISH, mitochondrial testing, and repeat-expansion testing are not first-line tests for classic FFI.

Ancillary findings. PSG is particularly informative because it directly measures the defining physiological disturbance. FDG-PET may reveal thalamic and cingulate/cortical hypometabolism before major structural atrophy. Routine MRI can be normal or nonspecific and often lacks the classic cortical-ribbon/basal-ganglia diffusion pattern of sporadic CJD. EEG may show diffuse slowing but usually not the characteristic periodic sharp-wave complexes of typical sCJD. CSF 14-3-3, total tau, and RT-QuIC may be negative or less sensitive in FFI because neurodegeneration and seeding characteristics differ from sCJD; a negative result cannot exclude genetically confirmed FFI. The retrieved evidence did not support defensible FFI-specific sensitivity or specificity values.

Plasma neurofilament light chain has been reported as increased and is a candidate progression biomarker, but it is a nonspecific axonal-injury marker and not a replacement for PRNP testing. (thune2023geneticvariantsassociated pages 9-10)

Differential diagnosis: sporadic fatal insomnia; MM2-thalamic sCJD; other genetic prion diseases; autoimmune/paraneoplastic encephalitis; Lewy-body disease; frontotemporal dementia; multiple-system atrophy; spinocerebellar ataxia; primary psychiatric disease; severe primary insomnia; and toxic-metabolic encephalopathy. Sporadic fatal insomnia lacks the causal familial PRNP haplotype.

Predictive testing in asymptomatic adults requires formal genetic counseling, informed consent, psychological support, and a protocol respecting the right not to know. Testing minors is generally inappropriate for an adult-onset condition without proven childhood intervention.

11. Outcome and prognosis

FFI is currently uniformly or nearly uniformly fatal after symptomatic onset; conventional 5- or 10-year survival statistics are not meaningful because most patients die within three years. Historical data from one large family showed mortality peaking near age 53 and only two carriers surviving beyond 60. (forloni2022preventivepharmacologicaltreatment pages 3-5)

Morbidity includes complete sleep disruption, autonomic instability, falls, loss of ambulation, dementia, dysphagia, malnutrition, aspiration, infection, and total dependence. Recovery after established disease is not documented. Codon-129 genotype, age at onset, and candidate modifier loci may influence duration, but no biomarker is validated for precise individual prognostication.

12. Treatment and current applications

There is no approved curative or proven disease-modifying treatment. Supportive practice includes sleep-symptom management, autonomic and cardiac monitoring, hydration and nutrition, swallowing/aspiration assessment, fall prevention, physical/occupational/speech therapy where feasible, psychiatric support, advance-care planning, and palliative/hospice care. Sedatives may transiently reduce distress but generally do not restore normal sleep architecture; polypharmacy can worsen confusion, falls, or respiratory risk. (forloni2022preventivepharmacologicaltreatment pages 1-2)

Doxycycline. The DOXIFF preventive study used doxycycline because preclinical studies suggested interference with β-sheet/aggregate formation plus antioxidant and anti-inflammatory effects. Ten D178N carriers aged 44–53 received 100 mg/day doxycycline hyclate, while 15 noncarriers received placebo under a genotype-concealing design. Follow-up was planned for ten years; success required fewer than four incident cases. Assessments included biennial neurologic/instrumental visits, annual neuropsychology, six-monthly laboratory sampling, and PSG. The absence of a surrogate endpoint forced comparison with historical incidence. Earlier randomized doxycycline treatment in symptomatic CJD was negative, reinforcing the view that intervention after extensive neurodegeneration may be too late. Published material retrieved here establishes feasibility and design, not proven prevention. (forloni2022preventivepharmacologicaltreatment pages 2-3, forloni2022preventivepharmacologicaltreatment pages 3-5)

Current translational direction. PrP lowering is attractive because reducing substrate PrP should act upstream of conformational propagation. Relevant registered programs include ION717, NCT06153966 (phase 1/2 PrP-lowering antisense program), NCT07444580 (phase 1 PrP-targeting siRNA safety/mechanism study), NCT05124392 (at-risk biomarker profiling), and genetic-prion natural-history studies. Eligibility and status must be confirmed directly at ClinicalTrials.gov. These studies are relevant to FFI but do not yet demonstrate clinical benefit.

Suggested MAXO labels: genetic counseling, molecular genetic testing, polysomnography, neurological examination, neuropsychological assessment, autonomic monitoring, nutritional support, physical therapy, speech therapy, palliative care, clinical trial participation, and preventive pharmacotherapy. Suggested CHEBI entity: doxycycline.

13. Prevention

There is no lifestyle, vaccine, or environmental primary prevention for a person who already carries the pathogenic allele. Mendelian transmission can be prevented or reduced through nondirective reproductive counseling, preimplantation genetic testing for monogenic disease, prenatal diagnosis, donor gametes, or choosing not to have genetically related children. Predictive testing and cascade testing are secondary-prevention/risk-identification measures, not treatment.

Tertiary prevention consists of early recognition of dysphagia, aspiration, falls, malnutrition, autonomic instability, pressure injury, and caregiver distress. At-risk adults may consider longitudinal natural-history or prevention studies. The unusual DOXIFF design preserved participants’ desire not to learn their genotype while allowing preventive research, illustrating the central ethical importance of autonomy in FFI families. (forloni2022preventivepharmacologicaltreatment pages 3-5, forloni2022preventivepharmacologicaltreatment pages 1-2)

14. Other species and natural disease

No naturally occurring veterinary disease is recognized as an exact ortholog of human D178N-129M FFI. Other mammals develop natural prion diseases—scrapie in sheep/goats, bovine spongiform encephalopathy, chronic wasting disease in cervids, and feline transmissible spongiform encephalopathy—but these are not FFI and usually arise from different strains, exposure routes, and host PRNP genotypes. Prion mechanisms and PRNP orthologs are evolutionarily conserved, enabling comparative research, but there is no evidence that human FFI is zoonotic or naturally transmitted from FFI families to animals.

Relevant taxa for comparative annotation include Homo sapiens (NCBI Taxon 9606) and Mus musculus (10090). Breed ontology is not applicable to the human disorder.

15. Model organisms

Models include transgenic or knock-in mice expressing FFI-associated mutant PrP, prion-inoculated mice, cultured cells expressing mutant PRNP, protein-conversion assays, and patient-derived cellular systems. D178N/129M mouse models can reproduce mutant-PrP accumulation, selective neurologic injury, sleep/circadian abnormalities, and molecular changes involving mitochondrial/ribosomal programs. Cell-type-specific translatome studies implicate astrocytes, glutamatergic neurons, and GABAergic neurons and suggest that molecular responses can precede EEG or overt histopathology.

Their limitations are important: mouse sleep architecture, lifespan, PRNP expression, strain background, and prion conformers differ from humans; some models require overexpression or inoculation and do not fully reproduce the human thalamic-autonomic syndrome. Consequently, therapeutic success in mice is hypothesis-generating rather than predictive of human efficacy. Candidate-model resources include MGI, IMSR, EMMA, and MMRRC.

Knowledge-base annotation summary

The following compact mapping separates robust evidence from suggested ontology labels requiring release-specific curator verification.

Domain Evidence-backed finding Suggested ontology terms/identifiers Evidence type/strength
Disease entity Fatal familial insomnia (FFI) is an ultra-rare inherited human prion disease with insomnia, dysautonomia, progressive neurologic decline, and death typically within months after onset (forloni2022preventivepharmacologicaltreatment pages 2-3, thune2023geneticvariantsassociated pages 1-2, forloni2022preventivepharmacologicaltreatment pages 1-2) Disease label: Fatal familial insomnia; MONDO: curator verification needed; OMIM: curator verification needed; Orphanet: curator verification needed; MeSH/ICD: curator verification needed Human clinical/review; moderate-strong
Causal gene/variant Core causal genotype is germline PRNP p.Asp178Asn (D178N) in cis with methionine at codon 129 on the mutant allele; autosomal dominant inheritance (thune2023geneticvariantsassociated pages 1-2, thune2023geneticvariantsassociated pages 2-4, forloni2022preventivepharmacologicaltreatment pages 1-2) PRNP (HGNC: curator verification needed); sequence variant: p.Asp178Asn / D178N; codon 129 Met on mutant allele; inheritance: autosomal dominant Human genetic; strong
Penetrance/risk Penetrance is described as very high; one large Italian kindred report summarized ~95% penetrance with 46 cases and 2 apparent non-penetrant individuals (forloni2022preventivepharmacologicaltreatment pages 2-3) Inheritance annotation: age-dependent/high penetrance; family history present in many kindreds Human family data; moderate
Onset/natural history Age at onset is highly variable, reported from 19-76 years; average around 51 years; typical disease duration ~6-36 months after symptom onset (thune2023geneticvariantsassociated pages 1-2, thune2023geneticvariantsassociated pages 2-4) HPO: Adult onset; Progressive neurologic deterioration; Reduced lifespan; Fatal outcome Human cohort/review; strong
Genetic modifiers Codon 129 on the non-mutated allele modifies phenotype but does not fully predict onset; WES study identified candidate modifier loci NR1H5P, GNA13P1, EXOC1L, SRSF11, MSANTD3 associated with later onset (thune2023geneticvariantsassociated pages 1-2, thune2023geneticvariantsassociated pages 6-8, thune2023geneticvariantsassociated pages 8-9) Modifier genes: NR1H5P, GNA13P1, EXOC1L, SRSF11, MSANTD3; note: provisional disease modifiers Human exploratory genomics; preliminary-moderate
Core phenotypes Hallmark manifestations include progressive insomnia/sleep loss, altered sleep-wake rhythm, autonomic dysfunction, dementia/cognitive decline, and motor signs (forloni2022preventivepharmacologicaltreatment pages 2-3, thune2023geneticvariantsassociated pages 1-2, forloni2022preventivepharmacologicaltreatment pages 1-2) HPO labels: Insomnia; Sleep disturbance; Abnormality of circadian rhythm; Autonomic nervous system dysfunction; Dementia; Cognitive impairment; Gait disturbance; Ataxia/parkinsonism/motor signs (IDs for curator verification) Human clinical/review; strong
Phenotype severity/course Disease course is progressive, severe, and usually fatal without remission; symptom heterogeneity is substantial even among patients sharing the same PRNP core genotype (thune2023geneticvariantsassociated pages 1-2, thune2023geneticvariantsassociated pages 8-9) HPO labels: Progressive neurologic deterioration; Variable expressivity; Lethal phenotype Human cohort/review; strong
Primary anatomy Selective vulnerability centers on thalamus, especially anterior and dorsomedial/mediodorsal thalamic nuclei; additional involvement includes inferior olive and entorhinal cortex (forloni2022preventivepharmacologicaltreatment pages 2-3, thune2023geneticvariantsassociated pages 1-2) UBERON labels: thalamus; mediodorsal thalamic nucleus; anterior thalamic nuclei; inferior olivary nucleus; entorhinal cortex (IDs for curator verification) Human neuropathology; strong
Tissue pathology Neuropathology features severe neuronal loss/depletion, astrocytic gliosis/astrogliosis, and pathologic prion protein deposition in vulnerable regions (forloni2022preventivepharmacologicaltreatment pages 2-3, thune2023geneticvariantsassociated pages 1-2) GO/pathology labels: neuron death; astrocyte activation; protein aggregation; prion protein amyloid formation; CL: neuron, astrocyte Human neuropathology; strong
Cell types implicated Disease mechanisms and omics literature implicate neurons and astrocytes; experimental translatome work also highlights GABAergic and glutamatergic neuronal populations (thune2023geneticvariantsassociated pages 6-8, thune2023geneticvariantsassociated pages 8-9) CL labels: neuron; astrocyte; GABAergic neuron; glutamatergic neuron (IDs for curator verification) Human omics + animal model/review; moderate
Molecular mechanism Pathogenesis is consistent with prion protein misfolding/conformational conversion leading to selective neurodegeneration, sleep/autonomic network failure, and downstream apoptotic/cellular stress pathways (forloni2022preventivepharmacologicaltreatment pages 2-3, thune2023geneticvariantsassociated pages 1-2, thune2023geneticvariantsassociated pages 6-8) GO labels: protein misfolding; amyloid fibril formation; programmed cell death; caspase-mediated cleavage; regulation of circadian rhythm Human genetics/neuropathology + experimental support; moderate-strong
Cellular processes Candidate pathways include programmed cell death, apoptotic cleavage/caspase-mediated processes, proteostasis disruption, cytoskeletal injury, circadian dysregulation, and mitochondrial/ribosomal decline (thune2023geneticvariantsassociated pages 6-8, thune2023geneticvariantsassociated pages 8-9) GO labels: apoptotic process; caspase-mediated cleavage; cytoskeleton organization; circadian rhythm; mitochondrial organization; ribosome biogenesis/translation Human WES pathway analysis + animal translatome; moderate
Subcellular compartments Omics/translatome evidence points to mitochondrial and ribosomal/translation machinery abnormalities early in disease-related responses (thune2023geneticvariantsassociated pages 6-8, thune2023geneticvariantsassociated pages 8-9) GO cellular component labels: mitochondrion; ribosome; cytoskeleton (IDs for curator verification) Human pathway inference + animal translatome; moderate
Proteomics/omics Human prion-disease brain proteomics found broad terminal-stage protein changes with shared pathways across FFI and other prion diseases, including oxidative phosphorylation, lysosome, protein export, and drug metabolism pathways (context from retrieved literature summarized alongside FFI-specific evidence) (thune2023geneticvariantsassociated pages 1-2) GO/Pathway labels: oxidative phosphorylation; lysosome; protein export Human tissue proteomics; limited-direct FFI specificity
Diagnostic approach Diagnosis is centered on clinical syndrome plus confirmatory PRNP testing; in at-risk or symptomatic subjects, longitudinal neurologic exam, neuropsychology, laboratory studies, and polysomnography are used in research/monitoring settings (forloni2022preventivepharmacologicaltreatment pages 3-5, forloni2022preventivepharmacologicaltreatment pages 1-2) MAXO labels: genetic testing; neurologic examination; neuropsychological assessment; polysomnography; laboratory monitoring Human clinical trial protocol/review; moderate
Biomarkers Plasma neurofilament light chain is cited as a biomarker in FFI-related literature, but quantitative performance was not available in the retrieved evidence here (thune2023geneticvariantsassociated pages 9-10) Biomarker label: neurofilament light chain; specimen: plasma Human biomarker citation in recent literature; limited in current evidence set
Imaging/electrophysiology Sleep studies/polysomnography are important in FFI evaluation; thalamic functional abnormalities are central, but specific sensitivity/specificity values for PSG, EEG, MRI, or FDG-PET were not available in the retrieved evidence here (forloni2022preventivepharmacologicaltreatment pages 3-5) MAXO labels: polysomnography; electroencephalography; brain MRI; FDG-PET (IDs for curator verification) Human clinical context; limited-direct quantitative evidence
Supportive treatment No curative therapy is established; care is mainly palliative/supportive, targeting neurologic, sleep, and autonomic complications (forloni2022preventivepharmacologicaltreatment pages 1-2) MAXO labels: palliative care; supportive care; symptom management; autonomic monitoring Human clinical/review; strong for absence of cure
Investigational drug therapy Doxycycline has been tested as preventive/repurposed therapy in at-risk carriers due to anti-prion and neuroprotective rationale; 10 D178N carriers received 100 mg/day in the DOXIFF protocol (forloni2022preventivepharmacologicaltreatment pages 2-3, forloni2022preventivepharmacologicaltreatment pages 3-5) CHEBI/drug label: doxycycline; MAXO labels: preventive pharmacotherapy; oral antibiotic repurposing; clinical trial participation Human trial protocol + preclinical rationale; moderate
Doxycycline trial design DOXIFF enrolled 10 carriers (ages 44-53) on doxycycline and 15 non-carriers on placebo, with 10-year follow-up and blinded assessments; trial lacked validated surrogate biomarkers and relied on historical comparison (forloni2022preventivepharmacologicaltreatment pages 3-5) Trial ID: EudraCT 2010-022233-28; MAXO labels: longitudinal surveillance; preventive treatment trial Human interventional protocol; moderate
Current clinical trials Broader genetic-prion/PRNP-lowering trials now recruiting may be relevant to FFI families, including ION717 (NCT06153966, phase 1/2), PrP-targeting siRNA safety/mechanism study (NCT07444580, phase 1), and observational biomarker/natural-history studies (NCT05124392, NCT05746715, NCT07732608) ClinicalTrials.gov IDs: NCT06153966; NCT07444580; NCT05124392; NCT05746715; NCT07732608 Trial registry evidence; strong for existence/status, limited for efficacy
Prevention/genetic counseling For this Mendelian disease, prevention is mainly family-based risk assessment, predictive PRNP testing in appropriate counseling settings, and potential enrollment in surveillance/prevention studies (forloni2022preventivepharmacologicaltreatment pages 3-5, forloni2022preventivepharmacologicaltreatment pages 1-2) MAXO labels: genetic counseling; predictive genetic testing; cascade testing; clinical surveillance Human clinical/research practice; moderate
Model organisms Mouse models carrying FFI-associated PRNP mutations and prion-disease translatome systems are used to study selective vulnerability, early cell-type responses, and therapeutic hypotheses, but they may incompletely capture the full human sleep/autonomic syndrome (thune2023geneticvariantsassociated pages 8-9) Model labels: PRNP D178N/129M knock-in mouse (curator verification needed); CL labels: astrocyte, GABAergic neuron, glutamatergic neuron Animal model; moderate with translational limitations
Evidence gaps Important gaps in the currently retrieved evidence set: verified ontology numeric IDs; robust prevalence/incidence estimates specific to FFI; test sensitivity/specificity for PSG/EEG/MRI/PET/RT-QuIC in FFI; validated prognostic biomarkers; controlled efficacy data for any disease-modifying therapy; nonhuman natural disease analogs (forloni2022preventivepharmacologicaltreatment pages 1-2, thune2023geneticvariantsassociated pages 8-9, forloni2022preventivepharmacologicaltreatment pages 3-5) Curator action items: verify MONDO/OMIM/Orphanet/MeSH/ICD IDs; add PMID-linked diagnostic accuracy and epidemiology sources Evidence synthesis; strong for gap identification

Table: This compact table summarizes evidence-backed findings for fatal familial insomnia in a knowledge-base-ready format, including genetics, phenotypes, anatomy, mechanisms, diagnostics, treatment, and evidence gaps. It also flags ontology identifiers that should be curator-verified rather than inferred.

Evidence assessment and research gaps

The most robust claims are the D178N-129M causal haplotype, autosomal-dominant inheritance, progressive sleep/autonomic syndrome, selective thalamic degeneration, and rapidly fatal course. Major unresolved areas are FFI-specific incidence and prevalence; validated prodromal biomarkers; quantitative diagnostic performance of PSG, PET, RT-QuIC, and NfL; replication of onset-modifier loci; human single-cell/spatial datasets; and controlled evidence for any disease-modifying treatment. The 2023 WES investigators explicitly characterized their modifier work as a small pilot constrained by rarity, so its candidate genes should not yet influence counseling or clinical decisions. (thune2023geneticvariantsassociated pages 2-4, thune2023geneticvariantsassociated pages 8-9)

Key recent sources

  • Thüne K, et al. Genetic Variants Associated with the Age of Onset Identified by Whole-Exome Sequencing in Fatal Familial Insomnia. Cells. Published August 2023;12:2053. DOI/URL: https://doi.org/10.3390/cells12162053. Abstract: “We identified nineteen potential gene variants with a potential effect on the age of onset.” PMID was not supplied in the retrieved record. (thune2023geneticvariantsassociated pages 1-2, thune2023geneticvariantsassociated pages 2-4)
  • Forloni G, et al. Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement. Prion. Published June 2022;16:66–77. DOI/URL: https://doi.org/10.1080/19336896.2022.2083435. Abstract: the study “led to a clinical trial based on the repurposing of doxycycline” and included ten mutation carriers and 15 noncarriers. PMID was not supplied in the retrieved record. (forloni2022preventivepharmacologicaltreatment pages 3-5, forloni2022preventivepharmacologicaltreatment pages 1-2)

Curation caution: ontology and coding systems change independently of primary literature. OMIM/Orphanet identifiers above should be confirmed at ingestion, and current MONDO, ICD-11, MeSH, HPO, GO, CL, UBERON, CHEBI, and MAXO numeric IDs should be resolved against the knowledge base’s pinned ontology releases.

References

  1. (forloni2022preventivepharmacologicaltreatment pages 2-3): Gianluigi Forloni, Ignazio Roiter, Vladimiro Artuso, Manuel Marcon, Walter Colesso, Elviana Luban, Ugo Lucca, Mauro Tettamanti, Elisabetta Pupillo, Veronica Redaelli, Francesco Mariuzzo, Giulia Boscolo Buleghin, Alice Mariuzzo, Fabrizio Tagliavini, Roberto Chiesa, and Anna Ambrosini. Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement. Prion, 16:66-77, Jun 2022. URL: https://doi.org/10.1080/19336896.2022.2083435, doi:10.1080/19336896.2022.2083435. This article has 10 citations and is from a peer-reviewed journal.

  2. (thune2023geneticvariantsassociated pages 1-2): Katrin Thüne, Matthias Schmitz, John Wiedenhöft, Orr Shomroni, Stefan Göbel, Timothy Bunck, Neelam Younas, Saima Zafar, Peter Hermann, and Inga Zerr. Genetic variants associated with the age of onset identified by whole-exome sequencing in fatal familial insomnia. Cells, 12:2053, Aug 2023. URL: https://doi.org/10.3390/cells12162053, doi:10.3390/cells12162053. This article has 2 citations.

  3. (thune2023geneticvariantsassociated pages 2-4): Katrin Thüne, Matthias Schmitz, John Wiedenhöft, Orr Shomroni, Stefan Göbel, Timothy Bunck, Neelam Younas, Saima Zafar, Peter Hermann, and Inga Zerr. Genetic variants associated with the age of onset identified by whole-exome sequencing in fatal familial insomnia. Cells, 12:2053, Aug 2023. URL: https://doi.org/10.3390/cells12162053, doi:10.3390/cells12162053. This article has 2 citations.

  4. (forloni2022preventivepharmacologicaltreatment pages 3-5): Gianluigi Forloni, Ignazio Roiter, Vladimiro Artuso, Manuel Marcon, Walter Colesso, Elviana Luban, Ugo Lucca, Mauro Tettamanti, Elisabetta Pupillo, Veronica Redaelli, Francesco Mariuzzo, Giulia Boscolo Buleghin, Alice Mariuzzo, Fabrizio Tagliavini, Roberto Chiesa, and Anna Ambrosini. Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement. Prion, 16:66-77, Jun 2022. URL: https://doi.org/10.1080/19336896.2022.2083435, doi:10.1080/19336896.2022.2083435. This article has 10 citations and is from a peer-reviewed journal.

  5. (thune2023geneticvariantsassociated pages 8-9): Katrin Thüne, Matthias Schmitz, John Wiedenhöft, Orr Shomroni, Stefan Göbel, Timothy Bunck, Neelam Younas, Saima Zafar, Peter Hermann, and Inga Zerr. Genetic variants associated with the age of onset identified by whole-exome sequencing in fatal familial insomnia. Cells, 12:2053, Aug 2023. URL: https://doi.org/10.3390/cells12162053, doi:10.3390/cells12162053. This article has 2 citations.

  6. (forloni2022preventivepharmacologicaltreatment pages 1-2): Gianluigi Forloni, Ignazio Roiter, Vladimiro Artuso, Manuel Marcon, Walter Colesso, Elviana Luban, Ugo Lucca, Mauro Tettamanti, Elisabetta Pupillo, Veronica Redaelli, Francesco Mariuzzo, Giulia Boscolo Buleghin, Alice Mariuzzo, Fabrizio Tagliavini, Roberto Chiesa, and Anna Ambrosini. Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement. Prion, 16:66-77, Jun 2022. URL: https://doi.org/10.1080/19336896.2022.2083435, doi:10.1080/19336896.2022.2083435. This article has 10 citations and is from a peer-reviewed journal.

  7. (thune2023geneticvariantsassociated pages 6-8): Katrin Thüne, Matthias Schmitz, John Wiedenhöft, Orr Shomroni, Stefan Göbel, Timothy Bunck, Neelam Younas, Saima Zafar, Peter Hermann, and Inga Zerr. Genetic variants associated with the age of onset identified by whole-exome sequencing in fatal familial insomnia. Cells, 12:2053, Aug 2023. URL: https://doi.org/10.3390/cells12162053, doi:10.3390/cells12162053. This article has 2 citations.

  8. (thune2023geneticvariantsassociated pages 9-10): Katrin Thüne, Matthias Schmitz, John Wiedenhöft, Orr Shomroni, Stefan Göbel, Timothy Bunck, Neelam Younas, Saima Zafar, Peter Hermann, and Inga Zerr. Genetic variants associated with the age of onset identified by whole-exome sequencing in fatal familial insomnia. Cells, 12:2053, Aug 2023. URL: https://doi.org/10.3390/cells12162053, doi:10.3390/cells12162053. This article has 2 citations.

Artifacts